```
     FILE 'REGISTRY' ENTERED AT 14:29:40 ON 23 JUN 2010
                  EXP HEPARIN
                  EXP HEPARIN/CN
L1             1 S E3
                  EXP LEUCINE/CN
L2             2 S E3

     FILE 'HCAPLUS' ENTERED AT 14:30:18 ON 23 JUN 2010
L3           109 S L1 AND L2
L4        856946 S POWDER OR INHALER OR ASTHMA OR PULMONARY OR BRONCHITIS OR (CY
L5            14 S L3 AND L4
L6         45532 S L2
L7          1025 S L4 AND L6
L8         66856 S INHAL?
L9           137 S L7 AND L8
L10     1253967 S FINE OR PARTICLE
L11          113 S L9 AND L10
L12           50 S L11 AND (PY<2004 OR AY<2004 OR PRY<2004)
L13           44 S L12 NOT L5
```

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.22       0.22

FILE 'REGISTRY' ENTERED AT 14:29:40 ON 23 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 JUN 2010  HIGHEST RN 1228216-77-0
DICTIONARY FILE UPDATES:  22 JUN 2010  HIGHEST RN 1228216-77-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp heparin
E1            1     HEPAREMIN/BI
E2            1     HEPAREXINE/BI
E3         1510 --> HEPARIN/BI
E4            3     HEPARINA/BI
E5            1     HEPARINADSORBER/BI
E6           11     HEPARINAMIDE/BI
E7           28     HEPARINASE/BI
E8           14     HEPARINATE/BI
E9            2     HEPARINE/BI
E10           1     HEPARINIC/BI
E11           1     HEPARINIZED/BI
E12           2     HEPARINOID/BI

=> exp heparin/cn
E1            1     HEPAREMIN/CN
E2            1     HEPAREXINE/CN
E3            1 --> HEPARIN/CN
E4            1     HEPARIN (PHYSARUM POLYCEPHALUM STRAIN LU-353)/CN
E5            1     HEPARIN 3-PYRIDYLMETHYL ESTER/CN
E6            1     HEPARIN 4-HYDROXY-N,N-DIMETHYLBUTYRAMIDE/CN
E7            1     HEPARIN ACETATE/CN
E8            1     HEPARIN ACETYLGLUCOSAMINE DEACETYLASE/CN
E9            1     HEPARIN AFFIN REGULATORY PEPTIDE/CN
E10           1     HEPARIN BENZETHONIUM SALT/CN
E11           1     HEPARIN BENZYL ESTER/CN
E12           1     HEPARIN BENZYL ESTER SODIUM SALT/CN

=> s e3
L1            1 HEPARIN/CN
```

```
=> exp leucine/cn
E1            1     LEUCINANILIDE/CN
E2            1     LEUCINANILIDE, N-PHOSPHONO-L-ALANYL-, BIS(P-NITROBENZYL) EST
                    ER, L-/CN
E3            2 --> LEUCINE/CN
E4            1     LEUCINE B-NAPHTHYLAMIDASE/CN
E5            1     LEUCINE 2,2,2-TRICHLOROETHYL ESTER/CN
E6            1     LEUCINE 2,3-AMINOMUTASE/CN
E7            1     LEUCINE 2-BROMOETHYL ESTER HYDROCHLORIDE/CN
E8            1     LEUCINE 2-NAPHTHYLAMIDASE/CN
E9            1     LEUCINE 2-NAPHTHYLAMIDE/CN
E10           1     LEUCINE 2-OCTYLDODECYL ESTER/CN
E11           1     LEUCINE 2-OXOGLUTARATE TRANSAMINASE/CN
E12           1     LEUCINE 3-PHENYL-2-THIOHYDANTOIN/CN

=> s e3
L2            2 LEUCINE/CN

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               11.49      11.71

FILE 'HCAPLUS' ENTERED AT 14:30:18 ON 23 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Jun 2010  VOL 152 ISS 26
FILE LAST UPDATED: 22 Jun 2010  (20100622/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Apr 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1 and l2
         31508 L1
         45532 L2
L3         109 L1 AND L2

=> s powder or inhaler or asthma or pulmonary or bronchitis or (cystic fibrosis) or
bronchiectasis
```

```
        681738 POWDER
          2972 INHALER
         49121 ASTHMA
        120899 PULMONARY
          9073 BRONCHITIS
         21381 CYSTIC
         54922 FIBROSIS
         16173 CYSTIC FIBROSIS
                 (CYSTIC(W)FIBROSIS)
          1050 BRONCHIECTASIS
L4      856946 POWDER OR INHALER OR ASTHMA OR PULMONARY OR BRONCHITIS OR (CYSTI
               C FIBROSIS) OR BRONCHIECTASIS

=> s l3 and l4
L5          14 L3 AND L4

=> d l5 1-14 ti abs bib

L5   ANSWER 1 OF 14  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Development of inhalable formulations of anti-inflammatory drugs to
     potentially treat smoke inhalation injury in burn victims
AB   Injury arising from smoke inhalation is a significant mortality risk in
     severe burned patients.  Inflammatory processes are major contributors to
     the development of respiratory insufficiency owing to pulmonary
     edema, formation of airway fibrin clots and hypoxemia.  Anti-inflammatory
     and anti-coagulant drugs such as heparin and pentoxifylline are currently
     systemically administered for the treatment of smoke inhalation.  Delivery
     of these drugs in the form of inhalable particles could be an effective
     manner to achieve rapid targeted action for acceleration of the treatment.
     The study developed and characterized a series of spray-dried heparin and
     pentoxifylline dry powder formulations suitable for inhalation
     administration.  Drug particles were co-spray-dried with leucine in
     varying ratios.  Particle size anal. confirmed all powders (except 2%,
     weight/weight, pentoxifylline with 1%, weight/weight, leucine in spray-drying
feed
     solution) had particle size in the optimal range (≤5 μm) for deep
     lung drug deposition.  Leucine supplementation dramatically altered
     heparin surface topog. while pentoxifylline formulations were a mixture of
     elongated needles interspersed with wrinkly particles.  Addition of leucine
     improved fine particle fraction of heparin and pentoxifylline.  The study
     indicated manufacture of inhalable heparin and pentoxifylline was feasible and
     can potentially be an attractive delivery alternative to the more
     conventional systemic delivery route.
AN   2010:287685  HCAPLUS <<LOGINID::20100623>>
DN   152:534349
TI   Development of inhalable formulations of anti-inflammatory drugs to
     potentially treat smoke inhalation injury in burn victims
AU   Thai, A.; Xiao, J.; Ammit, A. J.; Rohanizadeh, R.
CS   Advanced Drug Delivery Group, Faculty of Pharmacy (A15), University of
     Sydney, Sydney, NSW, 2006, Australia
SO   International Journal of Pharmaceutics (2010), 389(1-2), 41-52
     CODEN: IJPHDE; ISSN: 0378-5173
PB   Elsevier B.V.
DT   Journal
LA   English
RE.CNT  43     THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 2 OF 14  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Liposomal dispersion and dry powder formulations comprising
     oligonucleotides having improved downstream processing properties
```

AB A pharmaceutical composition comprises: (A) one or more drug substances; (B) a lipid; (C) a co-lipid; and (D) a flowability enhancer, wherein the co-lipid and the flowability enhancer together form a liposomal dispersion that comprises lipid vesicles that encapsulate the one or more drug substances. The pharmaceutical composition is optionally dried to form a dry powder formulation that is free-flowing and preferably suitable for inhalation or nasal administration. A composition contains oligonucleotide A, which is an immunomodulatory oligonucleotide or immunomer with TLR9 agonist activity that is useful in the treatment of allergic inflammatory diseases, hydrogenated phosphatidylcholine, pegylated phosphatidylcholine, Ca phosphate, lactic acid, mannitol, bovine serum albumin and phosphate buffer salt.

AN 2009:260561 HCAPLUS <<LOGINID::20100623>>

DN 150:290754

TI Liposomal dispersion and dry powder formulations comprising oligonucleotides having improved downstream processing properties

IN Eskandar, Fadi

PA Novartis A.-G., Switz.

SO PCT Int. Appl., 62pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009027337	A1	20090305	WO 2008-EP61018	20080822
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2007-114981	A	20070824		
	EP 2007-123163	A	20071213		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy

AB Accumulation of inspissated secretions that are difficult to clear and congest the airways is a feature of lung disease in patients with cystic fibrosis (CF). These secretions restrict airflow, harbor infection and limit the delivery of inhaled drugs including gene therapy vectors to the underlying target cells. Unfractionated heparin (UFH) has mucolytic properties suggesting that it may be a useful therapeutic agent for lung disease in these patients. For the pulmonary delivery of UFH to patients with CF, the dry powder inhaler has potential advantages over systems using nebulized suspensions. However, spray-dried particles in the appropriate size range (1-5 m) may absorb atmospheric moisture, causing aggregation. UFH was cospray-dried with L-leucine (1%) to produce particles that are less cohesive than UFH alone and show good aerosolization performance. Rheol. anal. showed that spray-dried UFH and

UFH cospray-dried with L-leucine significantly reduce the elasticity and yield stress of CF sputum. The superior phys. properties of UFH/L-leucine indicate this is the preferred formulation for development as an inhaled mucolytic.

AN 2008:1343290 HCAPLUS <<LOGINID::20100623>>
DN 150:83600
TI Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy
AU Shur, Jagdeep; Nevell, Thomas G.; Ewen, Richard J.; Price, Robert; Smith, Andrew; Barbu, Eugen; Conway, Joy H.; Carroll, Mary P.; Shute, Janis K.; Smith, James R.
CS School of Pharmacy and Biomedical Sciences, Institute of Biomedical and Biomolecular Science, University of Portsmouth, Portsmouth, PO1 2DT, UK
SO Journal of Pharmaceutical Sciences (2008), 97(11), 4857-4868
CODEN: JPMSAE; ISSN: 0022-3549
PB Wiley-Liss, Inc.
DT Journal
LA English
OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Inhaler devices and bespoke pharmaceutical compositions
AB The present invention relates to inhaler devices and bespoke pharmaceutical dry powder composition to be dispensed using such inhaler devices for pulmonary administration. In particular, the present invention relates to the provision of passive inhaler devices and dry powder comps. which are specifically formulated and prepared to be efficiently dispensed by such devices to reproducibly achieve a high delivered dose of the pharmaceutically active agent. Thus, blends containing 5% or 10% budesonide and magnesium stearate were obtained by mechanofusion carried out for 60 min at approx. 4000 rpm, resulting in a high aerosolization efficiency.
AN 2008:555538 HCAPLUS <<LOGINID::20100623>>
DN 148:523645
TI Inhaler devices and bespoke pharmaceutical compositions
IN Morton, David
PA Vectura Group PLC, UK
SO PCT Int. Appl., 113pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008053253	A2	20080508	WO 2007-GB50674	20071105
WO 2008053253	A3	20081002		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2086523 A2 20090812 EP 2007-824886 20071105
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR
PRAI GB 2006-21957 A 20061103
WO 2007-GB50674 W 20071105
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Aerodynamically light porous dry powder inhaler formulations for targeted pulmonary deposition
AB ALPDPI formulations having targeted and enhanced pulmonary deposition with prolong residence time, method of preparation and administration thereof are provided for the prophylaxis/treatment/diagnosis of various pulmonary and systemic disorders. In a preferred embodiment, the ALPDPI formulations are made of a biodegradable, biocompatible material/s and have a tap d. less than 0.4 g/cm3, a geometric diameter between 5 m and 30m. The ALPDPI formulations are comprising of bioactive agent encapsulated or complexed or micro or nanosize in the form of or within vesicles/particles such as liposomes, lipid complexes, solid lipid microparticles, solid lipid nanoparticles, solid lipid complexes, polymeric microparticles or nanoparticles bioactive agent particles such as microparticles or nanoparticles or nanocrystals or nanosuspension or combination thereof which are dispersed in additive materials solution or dispersion before processing such as carbohydrates/polyols/hydrolyzed gelatin with or without amino acid or a mixture of amino acid/s, or surfactant/s such as natural/synthetic phospholipid/s, tween/s, span/s, poloxamer/s, protease inhibitors and permeation enhancers etc., alone or in combinations thereof. The ALPDPI formulations comprising of vesicles/particles offers advantage of altering favorably the pharmacokinetic profile of the bioactive agent/s which helps in effective management of pulmonary and systemic disorders. The ALPDPI formulations of bioactive agent/s may be effectively aerosolized alone or co-administered with coarse carrier for administration having enhanced FPF/respirable fraction to the specific sites of lungs in the effective prophylaxis/treatment/diagnosis of pulmonary or systemic disorders by using a high/medium/low resistance device.
AN 2007:393843 HCAPLUS <<LOGINID::20100623>>
DN 148:85834
TI Aerodynamically light porous dry powder inhaler formulations for targeted pulmonary deposition
IN Ambikanandan, Misra; Bhupal, Chougule Mahavir; Ganesh, S.; Kumar, Padhi Bijay
PA India
SO Indian Pat. Appl., 30pp.
CODEN: INXXBQ
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 2006MU00953	A	20060630	IN 2006-MU953	20060615
PRAI IN 2006-MU953		20060615		

L5 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
AB The present invention is concerned with a refinement of the processing of particles that are to form a dry powder formulation which is to be administered to the lung using a dry powder inhaler (DPI) device. In particular, the present invention provides the

processing of particles of active material, e.g., steroids, bronchodilators, β2-agonists, antimuscarinics, antihistamines, anti-inflammatory agents, etc., and particles of carrier material in the presence of additive material to provide a powder composition which exhibits excellent powder properties and which is economical to produce. Thus, a blend of micronized budesonide 5%, magnesium stearate (force control agent) 6%, and Sorbolac 400 89% was prepared by Mechanofusion at approx. 4000 rpm for 60 min or in a conventional food-processor style bladed mixer, with 2 parallel blades at 2000 rpm for 20 min. The blend obtained in the food-processor mixer gave lower fine particle fractions (FPFs), when compared to that of the mechanofused blend.

AN 2006:513206 HCAPLUS <<LOGINID::20100623>>

DN 145:14730

TI Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives

IN Morton, David

PA Vectura Limited, UK

SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006056812	A1	20060601	WO 2005-GB50211	20051123
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2589514	A1	20060601	CA 2005-2589514	20051123
	EP 1814521	A1	20070808	EP 2005-808842	20051123
	EP 1814521	B1	20100127		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101106975	A	20080116	CN 2005-80047073	20051123
	JP 2008520307	T	20080619	JP 2007-542131	20051123
	AT 456363	T	20100215	AT 2005-808842	20051123
	EP 2174653	A1	20100414	EP 2010-151576	20051123
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	PT 1814521	E	20100416	PT 2005-808842	20051123
	ES 2340599	T3	20100607	ES 2005-808842	20051123
	IN 2007CN02767	A	20070907	IN 2007-CN2767	20070625
	US 20080127972	A1	20080605	US 2007-791385	20070705
PRAI	GB 2004-25758	A	20041123		
	EP 2005-808842	A3	20051123		
	WO 2005-GB50211	W	20051123		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Nanoparticulate compositions of tubulin inhibitors for treatment of resistant cancers and other diseases

GI



I

AB The present invention is directed to novel pharmaceutical compns. comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors (I; R1 = H, alkyl, alkylaryl, acyl, aryl; R2 = H, alkyl, acyl, aryl, alkoxycarbonyl, aryloxycarbonyl, cycloalkoxycarbonyl, etc.; R3-6 = H, alkyl, halogen; A,B,C,D = C, N; X = H, OH, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, acyl, carboxy, alkoxy, etc.). A tubulin inhibitor is preferably of the indole chemical class, N-substituted indol-3-glyoxyamides, and more preferably N-(pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D 24851, Indibulin). Methods of making and using such compns. for the treatment of anti-tumor agent resistant cancers and other diseases are also described. For example, a suspension of D-24851 was prepared by mixing an aqueous surfactant solution containing 0.1% sodium deoxycholate, 2.2% glycerin, and 0.142% dibasic sodium phosphate with a solution of D-24851 and Poloxamer 188 in lactic acid. The total suspension weight was 2000 g, with a drug concentration of approx. 1%. The suspension was homogenized, lactic acid was removed and the suspension was homogenized again to give a nanosuspension with the mean particle size of approx. 325 nm.

AN 2006:470314 HCAPLUS <<LOGINID::20100623>>
DN 144:495330
TI Nanoparticulate compositions of tubulin inhibitors for treatment of resistant cancers and other diseases
IN Papadopoulos, Pavlos; Doty, Mark; Kipp, James E.; Roessler, Berthold
PA Baxter International Inc., USA; Baxter Healthcare S.A.; Raab, Gerhard
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006052712	A1	20060518	WO 2005-US39922	20051103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

```
            KG, KZ, MD, RU, TJ, TM
     AU 2005304952        A1    20060518    AU 2005-304952         20051103
     CA 2587276           A1    20060518    CA 2005-2587276        20051103
     US 20060110462       A1    20060525    US 2005-266518         20051103
     EP 1809279           A1    20070725    EP 2005-851355         20051103
          R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
              BA, HR, MK, YU
     CN 101090720         A     20071219    CN 2005-80037827       20051103
     JP 2008519036        T     20080605    JP 2007-540058         20051103
     BR 2005017652        A     20081014    BR 2005-17652          20051103
     IN 2007DN03092       A     20070831    IN 2007-DN3092         20070425
     MX 2007005434        A     20070710    MX 2007-5434           20070504
     KR 2007074610        A     20070712    KR 2007-710342         20070507
PRAI US 2004-626036P      P     20041108
     US 2005-642878P      P     20050111
     WO 2005-US39922      W     20051103
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 144:495330
OSC.G   3     THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 8 OF 14  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Pharmaceutical compositions
AB   The present invention relates to pharmaceutical compns. which are useful
     in the treatment of diseases where excess mucus is present in the
     respiratory tract, such as cystic fibrosis and chronic
     obstructive pulmonary disease.  In particular, the invention
     relates to pharmaceutical compns. for administration by pulmonary
     inhalation.  Thus, in a first aspect of the present invention, a composition
     for assisting mucus clearance is provided, the composition comprising one or
     more mucoactive agents for reducing crosslinking within the mucus; for
     diluting the mucus; and/or for digesting naked DNA and cell debris within the
     mucus.  Preferably, the composition according to the invention further has the
     effect of reducing inflammation.  In one embodiment of the present
     invention, the composition comprises one or more mucoactive agents together
     with an addnl. active agent such as an anti-inflammatory agent.  In a
     particularly preferred embodiment of the present invention, the mucoactive
     agent for reducing crosslinking is a glycosaminoglycan such as heparin.  A
     further group of mucoactive agents capable of assisting mucus clearance
     are amino acids.  Acetylcysteine (NAC) and the acetylcysteine salt derivative
     Nacystelyn (or NAL) are also effective mucoactive agents which are
     suitable for inclusion in the compns. of the present invention.
AN   2005:259852  HCAPLUS <<LOGINID::20100623>>
DN   142:329858
TI   Pharmaceutical compositions
IN   Morton, David; Ganderton, David; Staniforth, John; Kamlag, Yorick
PA   Vectura Limited, UK
SO   PCT Int. Appl., 60 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005025540       A2     20050324    WO 2004-GB3932         20040915
     WO 2005025540       A3     20050616
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
```

```
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    AU 2004271778         A1    20050324    AU 2004-271778         20040915
    CA 2538399            A1    20050324    CA 2004-2538399        20040915
    EP 1663151            A2    20060607    EP 2004-768478         20040915
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
    BR 2004014425         A     20061114    BR 2004-14425          20040915
    CN 1874757            A     20061206    CN 2004-80032679       20040915
    JP 2007505830         T     20070315    JP 2006-525902         20040915
    SG 146649             A1    20081030    SG 2008-6902           20040915
    NZ 545550             A     20090331    NZ 2004-545550         20040915
    RU 2363448            C2    20090810    RU 2006-112583         20040915
    KR 2006082865         A     20060719    KR 2006-705166         20060314
    MX 2006002952         A     20060920    MX 2006-2952           20060315
    NO 2006001254         A     20060411    NO 2006-1254           20060317
    ZA 2006002748         A     20070530    ZA 2006-2748           20060404
    IN 2006CN01269        A     20070629    IN 2006-CN1269         20060413
    US 20070065373        A1    20070322    US 2006-571184         20060717
PRAI GB 2003-21611        A     20030915
    GB 2003-27723         A     20031128
    WO 2004-GB3932        W     20040915
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5  ANSWER 9 OF 14  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI  Methods for preparing pharmaceutical compositions
AB  The present invention relates to improvements in dry powder
    formulations comprising a pharmaceutically active agent for administration
    by inhalation, and in particular to methods of preparing dry powder
    compns. with improved properties.  In particular, spray drying processes
    are adapted and adjusted to obtain active particles with higher fine
    particle fractions and fine particle doses.  Spray drying 1% heparin from
    10% methanol, ethanol and propan-1-ol resulted in a lowering of fine
    particle fraction from approx. 20% when spray dried from aqueous solvent using
    identical parameters to 2-6% fine particle fraction.
AN  2005:259847  HCAPLUS <<LOGINID::20100623>>
DN  142:303679
TI  Methods for preparing pharmaceutical compositions
IN  Morton, David; Kamlag, Yorick
PA  Vectura Limited, UK
SO  PCT Int. Appl., 71 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 8
    PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
    --------------      ----   --------    -------------------    --------
PI  WO 2005025535        A2    20050324    WO 2004-GB3938         20040915
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
           CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
           GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
           LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
```

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP	1663164	A2	20060607	EP 2004-768484	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US	20060292081	A1	20061228	US 2006-570902	20060619
PRAI GB	2003-21608	A	20030915		
GB	2004-9133	A	20040423		
WO	2004-GB3938	W	20040915		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Compositions and methods for the pulmonary delivery of aerosolized medicaments
AB According to the subject invention, dispersible dry powder pharmaceutical-based compns. are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 μm MMAD. Such compns. are of pharmaceutical grade purity. Examples are provided of zinc insulin, parathyroid hormone, interleukin-1 receptor, calcitonin, α1-antitrypsin, β-interferon, heparin, lipid genetic vector, and adenoviral vector formulations for pulmonary delivery. Formulations of growth hormones suitable for treatment of short stature or renal failure are claimed.
AN 2004:11058 HCAPLUS <<LOGINID::20100623>>
DN 140:65165
TI Compositions and methods for the pulmonary delivery of aerosolized medicaments
IN Platz, Robert M.; Patton, John S.; Foster, Linda; Eljamal, Mohammed
PA Nektar Therapeutics, USA
SO U.S., 12 pp., Cont.-in-part of U.S. 6,231,851.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6673335	B1	20040106	US 2000-616236	20000714
	EP 940154	A2	19990908	EP 1999-110369	19920702
	EP 940154	B1	20070418		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	EP 1693080	A2	20060823	EP 2006-9725	19920702
	EP 1693080	A3	20070725		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	AT 359842	T	20070515	AT 1999-110369	19920702
	ES 2284226	T3	20071101	ES 1999-110369	19920702

```
     US 5785049            A     19980728    US 1994-309691          19940921
     NZ 329747             A     20000825    NZ 1995-329747          19950207
     EP 1462096            A1    20040929    EP 2004-76082           19950207
     EP 1462096            B1    20081210
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
     EP 2036541            A1    20090318    EP 2008-21259           19950207
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     TW 576750             B     20040221    TW 1995-84101726        19950224
     US 6582728            B1    20030624    US 1995-423515          19950414
     WO 9531479            A1    19951123    WO 1995-US6008          19950515
        W:  AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
            GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
            MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
            TT, UA
        RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
            LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
            SN, TD, TG
     US 6231851            B1    20010515    US 1997-737724          19970714
     US 20020132787        A1    20020919    US 2001-978826          20011016
     US 20020192164        A1    20021219    US 2002-141044          20020507
     US 20030053959        A1    20030320    US 2002-141028          20020507
     US 6737045            B2    20040518
     US 20030086877        A1    20030508    US 2002-245705          20020918
     US 20040096400        A1    20040520    US 2003-612376          20030701
     US 7521069            B2    20090421
     US 20040096401        A1    20040520    US 2003-613078          20030701
     US 20050279349        A1    20051222    US 2003-693318          20031024
     JP 2006077032         A     20060323    JP 2005-350682          20051205
     US 20090203576        A1    20090813    US 2009-396525          20090303
PRAI US 1992-910048        A2    19920708
     US 1993-44358         B1    19930407
     US 1994-246034        B2    19940518
     US 1994-309691        A2    19940921
     US 1994-313707        B2    19940927
     US 1995-383475        B2    19950201
     US 1995-417507        B2    19950404
     US 1995-423515        A1    19950414
     WO 1995-US6008        W     19950515
     US 1997-737724        A2    19970714
     US 1991-724915        A     19910702
     EP 1992-914592        A3    19920702
     EP 1999-110369        A3    19920702
     US 1994-207472        A     19940307
     US 1994-232849        A1    19940425
     EP 1995-909506        A3    19950207
     EP 2004-76082         A3    19950207
     JP 1995-523456        A3    19950207
     NZ 1995-281112        A1    19950207
     US 1995-576885        A1    19951222
     US 1996-668036        A1    19960617
     US 1997-979024        A1    19971126
     US 1999-427075        A3    19991026
     US 1999-427836        A1    19991026
     US 1999-447753        A1    19991122
     US 2000-561690        A1    20000501
     US 2000-616236        A1    20000714
     US 2002-245706        A1    20020918
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   2     THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT  19    THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L5 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of stable particles in frozen aqueous matrix for pharmaceutical suspensions

AB The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical or cosmetic suspended in a frozen aqueous matrix and method for its preparation The composition is stable for a prolonged period of time, preferably 6 mo or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration. Thus, suspension was obtained from Poloxamer-188 2.2, sodium deoxycholate 0.1, glycerin 2.2, and nabumetone 1%.

AN 2003:319276 HCAPLUS <<LOGINID::20100623>>

DN 138:343861

TI Preparation of stable particles in frozen aqueous matrix for pharmaceutical suspensions

IN Kipp, James E.; Doty, Mark J.; Rebbeck, Christine L.; Brynjelsen, Sean; Teresa, Konkel Jamie

PA Baxter International Inc., USA

SO U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030077329	A1	20030424	US 2002-270267	20021011
	US 7112340	B2	20060926		
	CA 2463313	A1	20030501	CA 2002-2463313	20021018
	WO 2003035031	A1	20030501	WO 2002-US33270	20021018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	AU 2002337894	A1	20030506	AU 2002-337894	20021018
	AU 2002337894	B2	20070712		
	EP 1435909	A1	20040714	EP 2002-773797	20021018
	EP 1435909	B1	20091202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005506999	T	20050310	JP 2003-537598	20021018
	CN 1750811	A	20060322	CN 2002-820792	20021018
	AT 450250	T	20091215	AT 2002-773797	20021018
	ES 2340261	T3	20100601	ES 2002-773797	20021018
	IN 2004DN00885	A	20091211	IN 2004-DN885	20040406
	MX 2004003675	A	20040723	MX 2004-3675	20040419
	US 20060222710	A1	20061005	US 2006-425122	20060619
	US 20060222711	A1	20061005	US 2006-425125	20060619
PRAI	US 2001-347548P	P	20011019		
	US 2002-270267	A	20021011		
	WO 2002-US33270	W	20021018		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Spray-drying a drug and a hydrophobic amino acid for pharmaceuticals

AB According to the subject invention, dispersible dry powder pharmaceutical-based compns. are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition has a moisture content of <10% water, usually below about 5% and preferably <3%; a particle size of 1.0-5.0 μm [mass median diameter; (MMD)], usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of >60%; and an aerosol particle size distribution of 1.0-45.0 μm mass median aerodynamic diameter Such compns. are of pharmaceutical grade purity. A 26.7% human calcitonin formulation was achieved by combining 1.9 mg human calcitonin/ 1.0 mL water with 4.3 mg/mL mannitol and 0.9 mg/mL citrate buffer at pH 3.85. A dry powder of the 26.7% human calcitonin formulation was produced by spray drying. The final 26.7% human calcitonin dry powder composition contained 60% mannitol and 13.3% citrate. The formulation contained 0.71% moisture. The particle size distribution of the composition was determined to be 1.33 MMD.

AN 2002:290686 HCAPLUS <<LOGINID::20100623>>

DN 136:299752

TI Spray-drying a drug and a hydrophobic amino acid for pharmaceuticals

IN Platz, Robert M.; Patton, John S.; Foster, Linda; Eljamal, Mohammed

PA Inhale Therapeutic Systems, USA

SO U.S., 11 pp., Cont. of U.S. Ser. No. 737,724.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6372258	B1	20020416	US 1999-447753	19991122
	EP 940154	A2	19990908	EP 1999-110369	19920702
	EP 940154	B1	20070418		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	EP 1693080	A2	20060823	EP 2006-9725	19920702
	EP 1693080	A3	20070725		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	AT 359842	T	20070515	AT 1999-110369	19920702
	ES 2284226	T3	20071101	ES 1999-110369	19920702
	US 5607915	A	19970304	US 1994-232849	19940425
	US 5785049	A	19980728	US 1994-309691	19940921
	NZ 329747	A	20000825	NZ 1995-329747	19950207
	EP 1462096	A1	20040929	EP 2004-76082	19950207
	EP 1462096	B1	20081210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	EP 2036541	A1	20090318	EP 2008-21259	19950207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	TW 576750	B	20040221	TW 1995-84101726	19950224
	US 6582728	B1	20030624	US 1995-423515	19950414
	WO 9531479	A1	19951123	WO 1995-US6008	19950515
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5814607	A	19980929	US 1996-625586	19960328
	US 6231851	B1	20010515	US 1997-737724	19970714
	US 6080721	A	20000627	US 1998-128401	19980803

	US 7456150	B1	20081125	US 2000-577264	20000522
	US 20020132787	A1	20020919	US 2001-978826	20011016
	US 20020127188	A1	20020912	US 2002-66106	20020201
	US 20020192164	A1	20021219	US 2002-141044	20020507
	US 20030053959	A1	20030320	US 2002-141028	20020507
	US 6737045	B2	20040518		
	US 20030086877	A1	20030508	US 2002-245705	20020918
	US 20030171282	A1	20030911	US 2002-245707	20020918
	US 7300919	B2	20071127		
	US 20030129141	A1	20030710	US 2003-355578	20030131
	US 6921527	B2	20050726		
	US 20030185765	A1	20031002	US 2003-388814	20030314
	US 20040096400	A1	20040520	US 2003-612376	20030701
	US 7521069	B2	20090421		
	US 20040096401	A1	20040520	US 2003-613078	20030701
	US 20050279349	A1	20051222	US 2003-693318	20031024
	JP 2006077032	A	20060323	JP 2005-350682	20051205
	US 20080075782	A1	20080327	US 2007-981198	20071030
	US 20090203576	A1	20090813	US 2009-396525	20090303
PRAI	US 1992-910048	A2	19920708		
	US 1993-44358	A1	19930407		
	US 1994-232849	A1	19940425		
	US 1994-246034	A1	19940518		
	US 1994-309691	A1	19940921		
	US 1994-313707	A1	19940927		
	US 1995-383475	A1	19950201		
	US 1995-417507	A2	19950404		
	US 1995-423515	A1	19950414		
	WO 1995-US6008	W	19950515		
	US 1997-737724	A2	19970714		
	US 1991-724915	A	19910702		
	EP 1992-914592	A3	19920702		
	EP 1999-110369	A3	19920702		
	US 1992-953397	B1	19920929		
	US 1994-207472	A	19940307		
	EP 1995-909506	A3	19950207		
	EP 2004-76082	A3	19950207		
	JP 1995-523456	A3	19950207		
	NZ 1995-281112	A1	19950207		
	US 1995-576885	A1	19951222		
	US 1996-625586	A3	19960328		
	US 1996-668036	A1	19960617		
	US 1997-979024	A1	19971126		
	US 1998-128401	A1	19980803		
	US 1999-427075	A3	19991026		
	US 1999-427836	A1	19991026		
	US 1999-447753	A1	19991122		
	US 2000-561690	A1	20000501		
	US 2000-577264	A1	20000522		
	US 2000-616236	A1	20000714		
	US 2002-66106	B1	20020201		
	US 2002-245706	A1	20020918		
	US 2002-245707	A1	20020918		
	US 2003-355578	A1	20030131		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Dry powder compositions having improved dispersivity

AB The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject. The surface tension of several representative di- and tripeptides and proteins was determined and highly surface active peptides include dileucine and trileucine.

AN 2001:338322 HCAPLUS <<LOGINID::20100623>>
DN 134:357557

TI Dry powder compositions having improved dispersivity

IN Lechuga-Ballesteros, David; Kuo, Mei-Chang
PA Inhale Therapeutic Systems, Inc., USA

SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032144	A1	20010510	WO 2000-US9785	20000412
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2389219	A1	20010510	CA 2000-2389219	20000412
	CA 2389219	C	20090623		
	AU 2000042353	A	20010514	AU 2000-42353	20000412
	AU 775565	B2	20040805		
	EP 1223915	A1	20020724	EP 2000-922117	20000412
	EP 1223915	B1	20051221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003513031	T	20030408	JP 2001-534349	20000412
	HU 2003001851	A2	20030929	HU 2003-1851	20000412
	HU 2003001851	A3	20060728		
	NZ 518401	A	20040130	NZ 2000-518401	20000412
	CN 1188111	C	20050209	CN 2000-814989	20000412
	AT 313318	T	20060115	AT 2000-922117	20000412
	EP 1666028	A1	20060607	EP 2005-27610	20000412
	EP 1666028	B1	20100324		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	ES 2254164	T3	20060616	ES 2000-922117	20000412
	IL 149085	A	20070515	IL 2000-149085	20000412
	TW 310688	B	20090611	TW 2000-89106941	20000412
	AT 461692	T	20100415	AT 2005-27610	20000412
	US 6518239	B1	20030211	US 2000-548759	20000413
	ZA 2002002855	A	20030821	ZA 2002-2855	20020411
	NO 2002001800	A	20020624	NO 2002-1800	20020417
	MX 2002004193	A	20021213	MX 2002-4193	20020426
	IN 228909	A1	20090320	IN 2002-CN614	20020426
	US 20030186894	A1	20031002	US 2002-313343	20021206
	US 6835372	B2	20041228		
	US 20050147567	A1	20050707	US 2004-985509	20041110
	US 7482024	B2	20090127		

```
     US 20090117193       A1    20090507    US 2008-343365         20081223
PRAI US 1999-162451P      P     19991029
     US 1999-164236P      P     19991108
     US 1999-172769P      P     19991220
     US 2000-178383P      P     20000127
     US 2000-178415P      P     20000127
     EP 2000-922117       A3    20000412
     WO 2000-US9785       W     20000412
     US 2000-548759       A1    20000413
     US 2002-313343       A1    20021206
     US 2004-985509       A3    20041110
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   39     THERE ARE 39 CAPLUS RECORDS THAT CITE THIS RECORD (49 CITINGS)
RE.CNT  3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 14 OF 14  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Drug delivery systems comprising pharmacological agents encapsulated with
     proteinoids
AB   A pharmacol. active agent is encapsulated within proteinoid microspheres
     having diameter of ≤10 μm and formed from linear thermal
     condensation polymers of mixed amino acids.  The microspheres protect the
     active agent from deleterious conditions within the gastrointestinal tract
     and release the active agent in the bloodstream or other targets.  A mixture
     of aspartic acid, arginine-HCl, isoleucine, and glycerol was heated to
     yield a solid proteinoid material, which was ground to a fine
     powder.  The powdered proteinoid was mixed with an aqueous solution of
     porcine insulin crystals to give insulin-bearing microspheres.  The
     microsphere suspension was orally administered to rats and the decrease in
     blood glucose was observed
AN   1993:11756  HCAPLUS <<LOGINID::20100623>>
DN   118:11756
OREF 118:2201a,2204a
TI   Drug delivery systems comprising pharmacological agents encapsulated with
     proteinoids
PA   Clinical Technologies Associates, Inc., USA
SO   Israeli, 33 pp.
     CODEN: ISXXAQ
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   IL 84935             A     19920115    IL 1987-84935          19871223
PRAI IL 1987-84935               19871223


=> s l2
L6       45532 L2

=> s l4 and l6
L7        1025 L4 AND L6

=> s inhal?
L8       66856 INHAL?

=> s l7 adn l8
MISSING OPERATOR L7 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
```

```
=> s 17 and 18
L9          137 L7 AND L8

=> s fine or particle
        377805 FINE
        932885 PARTICLE
L10    1253967 FINE OR PARTICLE

=> s l9 and l10
L11         113 L9 AND L10

=> s l11 and (PY<2004 or AY<2004 or PRY<2004)
      24051141 PY<2004
       4831495 AY<2004
       4305517 PRY<2004
L12          50 L11 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l12 not l5
L13          44 L12 NOT L5

=> d l13 1-44 ti abs bib

L13  ANSWER 1 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Use of simple hydrophobic amino acids to form porous microparticles
     including phospholipid, for pulmonary drug delivery
AB   Particles having a tap d. of less than 0.4 g/cm3 include a hydrophobic
     amino acid or salt thereof and a therapeutic, prophylactic or diagnostic
     agent or any combination thereof.  Preferred particles include a
     phospholipid, have a median geometric diameter between about 5 and about 30
     μ and an aerodynamic diameter between about 1 and about 5 μ.  The
     particles can be formed by spray-drying and are useful for delivery to the
     pulmonary system.  Thus, particles including 4% albuterol sulfate,
     60% DPPC and 36% leucine, alanine or glycine were formed by spray-drying.
     They exhibited mass median aerodynamic diams. of 2.38, 3.17, and 5.35
     μm, volumetric median geometric diams. of 10.28, 11.48, and 13.09
     μm, and densities of 0.054, 0.076, and 0.167 g/cm3, resp.  The data
     showed that all three amino acids were useful in forming particles
     suitable for pulmonary delivery; leucine and alanine
     formulations appeared best suited for delivery to the deep lung, while
     glycine formulations appeared more suitable for delivery to the central
     and upper airways.
AN   2007:863560  HCAPLUS <<LOGINID::20100623>>
DN   147:197422
TI   Use of simple hydrophobic amino acids to form porous microparticles
     including phospholipid, for pulmonary drug delivery
IN   Batycky, Richard P.; Lipp, Michael M.; Niven, Ralph W.
PA   Advanced Inhalation Research, Inc., USA
SO   U.S., 11pp., Cont.-in-part of U.S. Ser. No. 382,959.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   US 7252840           B1    20070807    US 2000-644320           20000823 <--
     US 6586008           B1    20030701    US 1999-382959           19990825 <--
     AT 319429            T     20060315    AT 2000-957716           20000823 <--
     EP 1637128           A2    20060322    EP 2005-77639            20000823 <--
     EP 1637128           A3    20080305
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, FI, CY
```

PT	1210068	E	20060731	PT 2000-957716	20000823 <--
ES	2258981	T3	20060916	ES 2000-957716	20000823 <--
US	20070104658	A1	20070510	US 2006-637353	20061212 <--
US	20080160092	A1	20080703	US 2007-873467	20071017 <--
US	20080160098	A1	20080703	US 2007-873472	20071017 <--
PRAI US	1999-382959	A2	19990825	<--	
EP	2000-957716	A3	20000823	<--	
US	2000-644320	A1	20000823	<--	
US	2006-637353	A3	20061212		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Trospium-containing compositions
AB The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 h. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray
drying a mixture comprising trospium and formoterol.
AN 2007:202111 HCAPLUS <<LOGINID::20100623>>
DN 146:259006
TI Trospium-containing compositions
IN Ehrich, Elliot; Deaver, Daniel; Clarke, Robert; Lipp, Michael M.
PA Advanced Inhalation Research, Inc., USA
SO U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 392,333.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070041912	A1	20070222	US 2005-550471	20050922 <--
	US 20040042970	A1	20040304	US 2003-392333	20030319 <--
	CA 2517265	A1	20041104	CA 2003-2517265	20030904 <--
	WO 2004093861	A1	20041104	WO 2003-US27618	20030904 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003273273	A1	20041119	AU 2003-273273	20030904 <--
	AU 2003273273	B2	20070208		
	EP 1603547	A1	20051214	EP 2003-755776	20030904 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514679	T	20060511	JP 2004-571157	20030904 <--
	NZ 541745	A	20091127	NZ 2003-541745	20030904 <--
	IN 2005DN03513	A	20070817	IN 2005-DN3513	20050808 <--

	MX	2005009629	A	20051018	MX 2005-9629	20050908 <--
	AU	2006220411	A1	20061012	AU 2006-220411	20060920 <--
	AU	2006220411	B2	20080626		
PRAI	US	2003-392333	A2	20030319	<--	
	WO	2003-US27618	W	20030904	<--	
	US	2002-366354P	P	20020320	<--	
	US	2002-366440P	P	20020320	<--	
	US	2002-366449P	P	20020320	<--	
	US	2002-366470P	P	20020320	<--	
	US	2002-366479P	P	20020320	<--	
	US	2002-366487P	P	20020320	<--	
	AU	2003-230689	A3	20030319	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L13 ANSWER 3 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
AB The present invention relates to inhalable formulations of apomorphine or its pharmaceutically acceptable salts or esters for use in treating sexual dysfunction. The present invention also relates to methods for preparing the apomorphine formulations as well as to methods for treatment of sexual dysfunction using said formulations and inhalers including said formulations. The present invention further relates to the use of apomorphine in the manufacture of a medicament for treating sexual dysfunction. Thus, 10 g of micronized apomorphine hydrochloride was added to 70 g of micronized lactose (Respitose SV 003), an addnl. 70 g of the lactose were added, and the resultant blend was passed through a 150 μm screen. The particle size distribution for a 200 μg dose of the apomorphine-lactose powder was fine particle dose (<5 μm) 117 μg, ultrafine particle dose (<2.5 μm) 80 μg, and MMAD (mass median aerodynamic diameter) 1.94 μm.
AN 2006:796630 HCAPLUS <<LOGINID::20100623>>
DN 145:217984
TI Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
IN Staniforth, John Nicholas; Morton, David; Tobyn, Michael; Eason, Stephen; Harmer, Quentin; Ganderton, David
PA UK
SO U.S. Pat. Appl. Publ., 51pp., Cont.-in-part of U.S. Ser. No. 621,964.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060178394	A1	20060810	US 2006-552231	20060421 <--
	US 20040204439	A1	20041014	US 2003-413022	20030414 <--
	US 20040204440	A1	20041014	US 2003-621964	20030717 <--
	WO 2004089374	A1	20041021	WO 2004-GB1627	20040414 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,		

TD, TG
PRAI US 2003-413022 A2 20030414 <--
US 2003-621964 A2 20030717 <--
WO 2004-GB1627 W 20040414
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L13 ANSWER 4 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
AB The present invention relates to improved formulations for the treatment of premature ejaculation and, in particular, relates to the administration of antidepressants by pulmonary inhalation for treating premature ejaculation. Various types of known antidepressants may be used, including tricyclic antidepressants, such as clomipramine. For example, clomipramine-HCl was micronized with an injector air pressure of 7 bar, grinding air pressure of 5 bar, and powder feed rate of approx. 10 g/min. The pre-micronized clomipramine was then blended in a pestle with a spatula with 5% Mg stearate and the blend was micronized with an injector air pressure of 7 bar, grinding air pressure of 1 bar and powder feed rate of approx. 10 g/min. Malvern (dry powder) particle size measurement gave a d(50) of 1.39 μm. Approx. 2 mg of the formulation was then loaded and sealed into a foil blister to be used in a powder inhaler device.
AN 2005:259861 HCAPLUS <<LOGINID::20100623>>
DN 142:322765
TI Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
IN Morton, David; Staniforth, John; Tobyn, Mike; Eason, Stephen; Harmer, Quentin; Ganderton, David
PA Vectura Limited, UK
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005025550	A1	20050324	WO 2004-GB3935	20040915 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004271779	A1	20050324	AU 2004-271779	20040915 <--
CA 2538997	A1	20050324	CA 2004-2538997	20040915 <--
EP 1663180	A1	20060607	EP 2004-768481	20040915 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014428	A	20061114	BR 2004-14428	20040915 <--
CN 1882318	A	20061220	CN 2004-80033670	20040915 <--
JP 2007505831	T	20070315	JP 2006-525903	20040915 <--
SG 146648	A1	20081030	SG 2008-6901	20040915 <--
RU 2362551	C2	20090727	RU 2006-112589	20040915 <--
NZ 545484	A	20090925	NZ 2004-545484	20040915 <--

```
     NO 2006000978         A      20060526    NO 2006-978             20060228 <--
     KR 2006117909         A      20061117    KR 2006-705140          20060314 <--
     MX 2006002951         A      20060920    MX 2006-2951            20060315 <--
     ZA 2006002747         A      20070425    ZA 2006-2747            20060404 <--
     IN 2006CN01283        A      20070629    IN 2006-CN1283          20060413 <--
     US 20070043030        A1     20070222    US 2006-570937          20060717 <--
PRAI GB 2003-21612         A      20030915  <--
     GB 2004-12562         A      20040604
     WO 2004-GB3935        W      20040915
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   2     THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 5 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Manufacture of benzodiazepine compositions for pulmonary
     inhalation
AB   The present invention relates to a pharmaceutical composition comprising a
     fine particle fraction (<5 μm) of at least 50%, and
     preferably between 70 and 99% or between 80 and 99%, and to methods of
     making particles.  In particular, the invention relates to methods of
     making composite active particles comprising a pharmaceutically active
     material, i.e., a benzodiazepine, such as clobazam or clonazepam, for
     pulmonary inhalation, the method comprising a jet
     milling process.  For example, a powder was prepared containing 80%
     clobazam, 18% micronized lactose (Respitose SV003, mean particle
     size 50 to 55 μm), and 2% leucine.  The formulation was then
     incorporated into blisters, each blister containing 4 mg of the powder
     .
AN   2005:259853  HCAPLUS <<LOGINID::20100623>>
DN   142:322761
TI   Manufacture of benzodiazepine compositions for pulmonary
     inhalation
IN   Morton, David; Ganderton, David; Staniforth, John; Tobyn, Mike; Eason,
     Stephen; Harmer, Quentin
PA   Vectura Limited, UK
SO   PCT Int. Appl., 76 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2005025541       A2     20050324    WO 2004-GB3942          20040915 <--
     WO 2005025541       A3     20050512
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004271783       A1     20050324    AU 2004-271783          20040915 <--
     CA 2539041          A1     20050324    CA 2004-2539041         20040915 <--
     EP 1670438          A2     20060621    EP 2004-768488          20040915 <--
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
```

```
     CN 1882314          A     20061220    CN 2004-80033645       20040915 <--
     JP 2007505832       T     20070315    JP 2006-525904         20040915 <--
     ZA 2006002747       A     20070425    ZA 2006-2747           20060404 <--
     IN 2006CN01285      A     20070629    IN 2006-CN1285         20060413 <--
     US 20070081948      A1    20070412    US 2006-571884         20060717 <--
PRAI GB 2003-21607       A     20030915  <--
     GB 2003-21608       A     20030915  <--
     GB 2003-21612       A     20030915  <--
     GB 2004-9133        A     20040423
     WO 2004-GB3942      W     20040915
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   4      THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 6 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Pharmaceutical compositions & devices for dispensing the same
AB   The present invention relates to dry powder pharmaceutical
     compns. comprising a benzodiazepine for administration by
     inhalation, and in particular, benzodiazepine dry powder
     compns. and inhaler devices for dispensing the same.  Co-jet
     milled formulations comprising clobozam, lecithin, and magnesium stearate
     exhibited exceptional fine particle fraction (FPFs)
     when dispensed from an active dry powder inhaler
     device.  The FPFs observed were significantly better that those of the
     mechanofused formulations and those formulations which did not include an
     additive material.  This improvement would appear to be largely due to
     reduced throat deposition, which was less than 8% for the co-jet milled
     formulations, compared to 15% for the pure drug and up to 27% for the
     mechanofused formulations.
AN   2005:259848  HCAPLUS <<LOGINID::20100623>>
DN   142:322760
TI   Pharmaceutical compositions & devices for dispensing the same
IN   Morton, David; Ganderton, David; Staniforth, John; Tobyn, Mike; Eason,
     Stephen; Harmer, Quentin
PA   Vectura Ltd., UK
SO   PCT Int. Appl., 65 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005025536        A2    20050324    WO 2004-GB3996         20040915 <--
     WO 2005025536        A3    20050512
     WO 2005025536        A9    20050811
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
     EP 1663155           A2    20060607    EP 2004-768542         20040915 <--
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     ZA 2006002747        A     20070425    ZA 2006-2747           20060404 <--
```

```
     US 20060257491        A1     20061116    US 2006-571146          20060717 <--
PRAI GB 2003-21607         A      20030915  <--
     GB 2003-21608         A      20030915  <--
     GB 2003-21612         A      20030915  <--
     GB 2004-9133          A      20040423
     WO 2004-GB3996        W      20040915
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   1      THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 7 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Devices and pharmaceutical compositions containing amino acids,
     phospholipids or stearates for enhancing dosing efficiency
AB   The present invention relates to enhancing the dosing efficiency of
     pharmaceutical dry powder formulations administered by
     pulmonary inhalation.  In particular, the present
     invention relates to the provision of dry powder
     inhalers and dry powder compns. which reproducibly
     achieve a much higher delivered dose of the pharmaceutically active agent
     than currently achieved, that is wherein upon actuation of the device, a
     dosing efficiency at 5 μm of at least 70% is achieved.  For example, a
     blend containing Pharmatose 150M 85.15%, Sorbolac 400 8.25%, micronized
     leucine 5.00%, and apomorphine hydrochloride 1.60% was prepared, and the
     blend was passed through a 212 μm sieve.  Thereafter, the blend (25 mg;
     400 μg apomorphine hydrochloride) was placed in capsules and tested in
     a Cyclohaler inhaler using an Anderson Cascade Impactor (ACI)
     testing device.  A delivered dose was 81% of the total dose, fine
     particle fraction (percent of the delivered dose <5 μm) was
     67%, fine particle dose (percent of the total dose <5
     μm) was 55%, a mass median aerodynamic diameter (MMAD) was 2.3 μm,
     fine particle dose was 220 μm, ultrafine
     particle dose (percent of the total dose <3 μm) was 44%,
     ultrafine particle dose was 175 μm, and ultrafine
     particle fraction was 53%.
AN   2004:927035  HCAPLUS <<LOGINID::20100623>>
DN   141:384314
TI   Devices and pharmaceutical compositions containing amino acids,
     phospholipids or stearates for enhancing dosing efficiency
IN   Staniforth, John; Morton, David; Tobyn, Michael; Eason, Stephen; Harmer,
     Quentin; Ganderton, David
PA   Vectura Ltd., UK
SO   PCT Int. Appl., 222 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2004093848        A2     20041104    WO 2004-GB1628         20040414 <--
     WO 2004093848        A3     20050428
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
```

TD, TG

US	20040204439	A1	20041014	US 2003-413022	20030414 <--
US	20040204440	A1	20041014	US 2003-621964	20030717 <--
AU	2004231342	A1	20041104	AU 2004-231342	20040414 <--
CA	2522158	A1	20041104	CA 2004-2522158	20040414 <--
EP	1617820	A2	20060125	EP 2004-727320	20040414 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP	2006522634	T	20061005	JP 2006-506130	20040414 <--
US	20060147389	A1	20060706	US 2005-552326	20051007
IN	2005CN02992	A	20070921	IN 2005-CN2992	20051114 <--
ZA	2006002747	A	20070425	ZA 2006-2747	20060404 <--
IN	2008CN05576	A	20090320	IN 2008-CN5576	20081016 <--
PRAI US	2003-413022	A	20030414 <--		
US	2003-621964	A	20030717 <--		
GB	2003-21612	A	20030915 <--		
WO	2004-GB1628	W	20040414		
IN	2005-CN2992	A3	20051114		

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation and pharmaceutical properties of salcatonin dry powder inhalations
AB The salcatonin dry powder inhalations (SCT-DPIs) A (mixture of mannitol and L-leucine) and B (mixture of mannitol and lactose) were prepared by spray-drying and their main pharmaceutical properties were studied. Dumping rate of SCT-DPI capsules and deposited fraction of SCT at effective part were determined according to Chinese Pharmacopeia 2000. Particle morphol. under different relative humidity (RH) was observed by scanning electron microphotograph, particle size and its distribution were determined by Malvem Mastersizer and the transition of amorphous state for carriers before and after spray- drying was studied by DTA and X-ray powder diffraction (XRPD). Dumping rates of SCT-DPIs A and B capsules were both above 10% and deposited fraction of SCT at effective part was above 90% for both A and B formulations, which were all in agreement with the standard of Chinese Pharmacopeia 2000. Powder particle of SCT-DPI A was round and existed one by one after keeping one month under 0, 23% and 52% RH, but aggregation could be observed under 75% RH; many particles which were also round agglomerated in SCT-DPI B even under zero RH; mean particle size of SCT-DPI A was 1.67 μm, which was much smaller than that of SCT-DPI B; in SCT-DPI A particle with empty core which was lighter than the same size particle with concreted core was observed It was shown by DTA that melted heat of L-leucine in SCT-DPI composed of mannitol and L-leucine was lower than that of L-leucine alone after spray-drying. It was confirmed by XRPD that diffraction intensity of carriers in SCT-DPIs decreased more than that of carriers before spray-drying. Round particle could be made when mannitol was added to carriers and ultra low d. carriers could be formed when L-leucine was added. It was suggested by SEM that DPIs should be kept under certain RH. Particle size and distribution of SCT-DPIs were in accordance with DPIs requirements. Complex spray-drying carriers formed amorphous state easier than single carrier.
AN 2004:727750 HCAPLUS <<LOGINID::20100623>>
DN 142:341575
TI Preparation and pharmaceutical properties of salcatonin dry powder inhalations
AU Xiong, Lianjie; Zhu, Jiabi
CS Zhongkun Pharmaceutical Research Institute, China Pharmaceutical

University, Nanjing, 210009, Peop. Rep. China
SO Yaoxue Xuebao (2003), 38(3), 218-222
CODEN: YHHPAL; ISSN: 0513-4870
PB Yaoxue Xuebao Bianjibu
DT Journal
LA Chinese
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L13 ANSWER 9 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Freeze-dried interferon-γ composition for transpulmonary administration and inhalation system therefor
AB The present invention provides a freeze-dried interferon-γ composition for transpulmonary administration which can maintain IFN-γ stably, and can be prepared into fine particles in a vessel at the time of use. A freeze-dried interferon-γ composition for transpulmonary administration of the present invention has the following properties: (1) containing at least one hydrophobic stabilizer selected from the group consisting of hydrophobic amino acids, dipeptides of hydrophobic amino acids, tripeptides of hydrophobic amino acids and derivs. of hydrophobic amino acids and salts thereof; at least one hydrophilic stabilizer selected from the group consisting of hydrophilic amino acids, dipeptides of hydrophilic amino acids, tripeptides of hydrophilic amino acids, derivs. of hydrophilic amino acids and salts thereof; and interferon-γ (2) a non- powder cake-like form; (3) a disintegration index of 0.015 or more; and (4) becoming fine particles having a mean particle diameter of 10 μm or less or a fine particle fraction of 10 % or more upon receipt of an air impact having an air speed of at least 1 m/s and an air flow rate of at least 17 mL/s.
AN 2004:531379 HCAPLUS <<LOGINID::20100623>>
DN 141:76771
TI Freeze-dried interferon-γ composition for transpulmonary administration and inhalation system therefor
IN Yamashita, Chikamasa; Ibaragi, Shigeru
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054605	A1	20040701	WO 2003-JP15957	20031212 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003285776	A1	20040709	AU 2003-285776	20031212 <--
	EP 1569681	A1	20050907	EP 2003-778884	20031212 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1726045	A	20060125	CN 2003-80106050	20031212 <--
	JP 2006509825	T	20060323	JP 2004-560629	20031212 <--
	US 20060057106	A1	20060316	US 2005-538781	20050610 <--
	IN 2005DN02516	A	20091030	IN 2005-DN2516	20050611 <--

```
PRAI JP 2002-363026       A     20021213  <--
    WO 2003-JP15957       W     20031212  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 10 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Novel dry powder inhalation system for transpulmonary
     administration
AB   It is intended to provide a novel dry powder inhalation
     system for transpulmonary administration which is suitable for
     transpulmonary administration.  This novel dry powder
     inhalation system for transpulmonary administration comprises :
     (1) a container having a freeze-dried composition for transpulmonary
     administration which is prepared by freeze-drying a liquid composition
containing a
     component in an undissolved state and has the following properties (i) to
     (iii): (i) being in the form of a non-powdery cake; (ii) having a
     disintegration index of 0.05 or more; and (iii) upon an air impact of an
     air speed of at least 1 m/s and an air flow rate of at least 17 mL/s,
     being disintegrated into fine particles having an average
     particle diameter (an aerodynamic particle diameter) of 10
     μm or less or an effective  particle rate of 10% or more;
     combined with (2) a means of applying the above-described air impact to
     the freeze-dried composition in the above-described container, and a means of
     discharging the powdery freeze-dried composition having been disintegrated into
     fine particles.  A freeze-dried inhalant composition was
     prepared from a cationic liposome (Lipofect AMINE 2000), a plasmid DNA
     (pEGFP-C2), and L-leucine.
AN   2004:531335  HCAPLUS <<LOGINID::20100623>>
DN   141:59762
TI   Novel dry powder inhalation system for transpulmonary
     administration
IN   Yamashita, Chikamasa; Akagi, Akitsuna; Fukunaga, Yuichiro
PA   Otsuka Pharmaceutical Co., Ltd., Japan
SO   PCT Int. Appl., 106 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2004054555       A1     20040701    WO 2003-JP15931        20031212 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CN 1516606           A      20040728    CN 2002-811941         20020614 <--
     CN 100427077         C      20081022
     CA 2507766           A1     20040701    CA 2003-2507766        20031212 <--
     AU 2003289051        A1     20040709    AU 2003-289051         20031212 <--
     AU 2003289051        B2     20080626
     EP 1579855           A1     20050928    EP 2003-778863         20031212 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

	BR 2003016754	A	20051025	BR 2003-16754	20031212	<--
	CN 1726014	A	20060125	CN 2003-80105876	20031212	<--
	CN 1323658	C	20070704			
	ZA 2005005312	A	20061025	ZA 2005-5312	20031212	<--
	NZ 540935	A	20070629	NZ 2003-540935	20031212	<--
	MX 2005006322	A	20050826	MX 2005-6322	20050613	<--
	US 20060073105	A1	20060406	US 2005-538837	20050613	<--
	US 20070065371	A2	20070322			
	US 7735485	B2	20100615			
	EG 23775	A	20070808	EG 2005-290	20050613	<--
	IN 2005DN02889	A	20070119	IN 2005-DN2889	20050629	<--
	IN 216513	A1	20080328			
	HR 2005000639	A2	20060731	HR 2005-639	20050712	<--
	HK 1082403	A1	20071012	HK 2006-102514	20060224	<--
	AU 2008200583	A1	20080228	AU 2008-200583	20080207	<--
PRAI	JP 2002-363158	A	20021213	<--		
	JP 2001-182504	A	20010615	<--		
	JP 2001-400871	A	20011228	<--		
	JP 2002-111131	A	20020412	<--		
	AU 2002-311213	A3	20020614	<--		
	WO 2003-JP15931	W	20031212	<--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Inhalable drug delivery particles comprising epinephrine and method of uses
AB The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compns. comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compns. are substantially dry and are substantially free of propellants. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
AN 2004:331569 HCAPLUS <<LOGINID::20100623>>
DN 140:344875
TI Inhalable drug delivery particles comprising epinephrine and method of uses
IN Batycky, Richard P.; Caponetti, Giovanni; Childs, Mariko; Ehrich, Elliot; Fu, Karen; Hrkach, Jeffrey S.; Li, Wen-I.; Lipp, Michael M.; Pan, Mei-Ling; Summa, Jason
PA USA
SO U.S. Pat. Appl. Publ., 60 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20040076588	A1	20040422	US 2003-607571	20030626	<--
	CA 2488976	A1	20040108	CA 2003-2488976	20030626	<--
	CA 2488976	C	20090825			
	WO 2004002551	A2	20040108	WO 2003-US20166	20030626	<--
	WO 2004002551	A3	20040812			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003280102 A1 20040119 AU 2003-280102 20030626 <--
AU 2003280102 B2 20070125
EP 1531794 A2 20050525 EP 2003-742233 20030626 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-393007P P 20020628 <--
US 2002-393716P P 20020702 <--
US 2002-425349P P 20021108 <--
WO 2003-US20166 W 20030626 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L13 ANSWER 12 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
AB This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone (DHEA), its analog(s) or salt(s) by itself or with a pharmaceutically or veterinary acceptable carrier or diluent, and having a particle size of about 0.1 μm to about 100 μm. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and/or a therapeutic kit. Spry drying of anhydrous DHEA sulfate and determination of respiratory dose is described.
AN 2004:120665 HCAPLUS <<LOGINID::20100623>>
DN 140:169659
TI Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
IN Leonard, Sherrya.; Johnson, Keith A.
PA Epigenesis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012653	A2	20040212	WO 2003-US18944	20030617 <--
WO 2004012653	A3	20040708		

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

```
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003276836        A1    20040223    AU 2003-276836          20030617 <--
     AU 2003276836        B2    20070510
     US 20040067920       A1    20040408    US 2003-462901          20030617 <--
     US 7405207           B2    20080729
     CA 2489124           A1    20041202    CA 2003-2489124         20030617 <--
     EP 1513509           A2    20050316    EP 2003-766816          20030617 <--
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003011883        A     20050405    BR 2003-11883           20030617 <--
     CN 1658884           A     20050824    CN 2003-813691          20030617 <--
     CN 100540007         C     20090916
     CN 1681520           A     20051012    CN 2003-813681          20030617 <--
     JP 2005537296        T     20051208    JP 2004-525996          20030617 <--
     IN 2004DN03700       A     20070420    IN 2004-DN3700          20041124 <--
     IN 236147            A1    20091009
     MX 2004012720        A     20070323    MX 2004-12720           20041215 <--
     US 20090087389       A1    20090402    US 2008-238403          20080925 <--
PRAI US 2002-389242P      P     20020617  <--
     US 2003-477987P      P     20030611  <--
     US 2003-462927       B1    20030617  <--
     WO 2003-US18944      W     20030617  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 13 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Dihydrate dehydroepiandrosterone and methods of treating asthma
     or chronic obstructive pulmonary disease using compositions
     thereof
AB   This invention relates to a powder formulation comprising a
     dihydrate dehydroepiandrosterone covalently bound to a sulfate, its
     analog(s) or salt(s) by itself and with a pharmaceutically or veterinarily
     acceptable carrier, and having a particle size of about 0.1
     μm to about 100 μm.  The formulation can be used to treat or prevent
     asthma, chronic obstructive pulmonary disease, lung
     inflammation, SARS, and other respiratory diseases or conditions.  The
     formulation may be prepared by jet milling, and may be delivered through the
     respiratory tract or other routes.  The formulation is provided in a
     device and a therapeutic kit.
AN   2003:1006714  HCAPLUS <<LOGINID::20100623>>
DN   140:47522
TI   Dihydrate dehydroepiandrosterone and methods of treating asthma
     or chronic obstructive pulmonary disease using compositions
     thereof
IN   Leonard, Sherry A.; Johnson, Keith A.
PA   Epigenesis Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2003105775       A2     20031224    WO 2003-US18945        20030617 <--
     WO 2003105775       A3     20040408
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
```

```
            TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2491846          A1    20031224    CA 2003-2491846         20030617 <--
    AU 2003269889       A1    20031231    AU 2003-269889          20030617 <--
    AU 2003269889       B2    20070419
    US 20040067920      A1    20040408    US 2003-462901          20030617 <--
    US 7405207          B2    20080729
    BR 2003011885       A     20050405    BR 2003-11885           20030617 <--
    EP 1553954          A2    20050720    EP 2003-751776          20030617 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1658884          A     20050824    CN 2003-813691          20030617 <--
    CN 100540007        C     20090916
    CN 1681520          A     20051012    CN 2003-813681          20030617 <--
    JP 2005530820       T     20051013    JP 2004-512683          20030617 <--
    IN 2004DN03618      A     20070420    IN 2004-DN3618          20041118 <--
    MX 2004012728       A     20060202    MX 2004-12728           20041215 <--
    US 20090087389      A1    20090402    US 2008-238403          20080925 <--
PRAI US 2002-389242P    P     20020617  <--
    US 2003-477987P     P     20030611  <--
    US 2003-462927      B1    20030617  <--
    WO 2003-US18945     W     20030617  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 140:47522
OSC.G   3     THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 14 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   a process of forming and modifying pharmaceutical particles
AB   The present invention relates to processes for forming particles containing
     drugs in a solution, changing the bulk or surface properties of a drug
     particle, and/or microencapsulating drug particles, and compns.
     produced thereby.  In some embodiments, the process described utilizes
     mech. agitation, more specifically low-frequency sonication, under
     controlled conditions, which provides mild shear forces during forming
     and/or precipitation to control the particle growth and mixing
     properties.  Particle size can range from <200 nm to >1 mm,
     depending on the processing conditions and application.  The process can
     be used to form a drug particle suspension, dry a wet
     powder slurry or suspension, as well as to improve the surface
     properties of the particle through conditioning the structure of
     the particle or particle surface and/or annealing the
     particle or particle surface.  Annealing or conditioning
     drug particles may be used to force an amorphous to crystalline transition,
     creating a more stable powder, or smooth a particle
     surface.  In addition, the process can be used to microencapsulate particles
     by suspending the microparticles in a non-solvent including a coating
     material (such as a biodegradable polymer) under controlled process
     conditions.  The powder compns. produced thereby possess
     improved properties including, but not limited to, improved flow and
     dispersibility, controlled bioadhesion, stability, resistance to moisture,
     dissoln./release profiles, and/or bioavailabilities.  This process, and
     the compns. produced, provide significant advantages in the manufacture of
     pharmaceutical particulate formulations, as well as biomedical,
     diagnostic, and chromatog. particulate compns., where sensitive
     macromols., such as proteins or DNA, are involved that would be degraded
     using more rigorous processing conditions or temps.  Thus, a solution of 10 g
```

lactose and 0.2 g leucine in water was agitated at 300-400 Torr for 24 h. A white powder was obtained containing particles of the size <10 μ.

AN 2003:875089 HCAPLUS <<LOGINID::20100623>>
DN 139:354491
TI a process of forming and modifying pharmaceutical particles
IN Talton, James D.; McConville, Christopher
PA USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003090717	A1	20031106	WO 2003-US11488	20030423 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003263024	A1	20031110	AU 2003-263024	20030423 <--
	US 20050175707	A1	20050811	US 2005-512345	20050419 <--
PRAI	US 2002-374844P	P	20020423	<--	
	WO 2003-US11488	W	20030423	<--	

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Inhalable sustained-release pharmaceutical formulations
AB The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising a phospholipid and leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or a combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1-46%; and leucine, wherein leucine is present in the particles in an amount of at least 46%, can contribute to sustained effect of the agent. Particles that comprise at least 46% leucine but that do not contain phospholipids do not exhibit these same sustained-release properties. Thus, a composition contained leucine 46, DPPC 46, and albuterol sulfate 8%.
AN 2003:777510 HCAPLUS <<LOGINID::20100623>>
DN 139:296969
TI Inhalable sustained-release pharmaceutical formulations
IN Basu, Sujit K.; Caponetti, Giovanni; Clark, Robert; Elbert, Katharina J.
PA Advanced Inhalation Research, Inc., USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
PI   WO 2003079885        A2    20031002    WO 2003-US8537         20030319 <--
     WO 2003079885        A3    20040212
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2478974           A1    20031002    CA 2003-2478974        20030319 <--
     AU 2003230689        A1    20031008    AU 2003-230689         20030319 <--
     AU 2003230689        B2    20060629
     EP 1487411           A2    20041222    EP 2003-723779         20030319 <--
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005520843        T     20050714    JP 2003-577722         20030319 <--
     AU 2006220411        A1    20061012    AU 2006-220411         20060920 <--
     AU 2006220411        B2    20080626
PRAI US 2002-366354P      P     20020320  <--
     US 2002-366440P      P     20020320  <--
     US 2002-366449P      P     20020320  <--
     US 2002-366470P      P     20020320  <--
     US 2002-366479P      P     20020320  <--
     US 2002-366487P      P     20020320  <--
     AU 2003-230689       A3    20030319  <--
     WO 2003-US8537       W     20030319  <--
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 16 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Inhalable formulations for sustained release
AB   The present invention is based, in part, on the unexpected discovery that
     aerosol particle formulations for pulmonary delivery
     of a therapeutic, prophylactic or diagnostic agent comprising an asym.
     phospholipid exhibit sustained release and/or sustained action of the
     agent.  In some embodiments, as an alternative to one or more asym.
     phospholipids or in addition to one or more asym. phospholipids, the instant
     particles comprise one or more glycerol fatty acid esters.  The present
     invention is directed to spray dried non-polymeric particles for
     pulmonary delivery and sustained release of a therapeutic,
     prophylactic or diagnostic agent.  In one embodiment, the particles
     comprise a combination of phospholipids wherein at least one of the
     phospholipids is an asym. phospholipid.  In another embodiment, the
     particles comprise one or more phospholipids and one or more glycerol
     fatty acid esters.  For example, a dry powder particle
     formulation contained 76% stearoylpalmitoyl phosphatidylcholine, 16%
     leucine, and 8% albuterol sulfate.
AN   2003:696715  HCAPLUS <<LOGINID::20100623>>
DN   139:219343
TI   Inhalable formulations for sustained release
IN   Basu, Sujit K.; Elbert, Katharina; Hrkach, Jeffrey; Caponetti, Giovanni
PA   Advanced Inhalation Research, Inc., USA
SO   PCT Int. Appl., 76 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

PI	WO 2003072080	A1	20030904	WO 2003-US5105	20030220 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003215334	A1	20030909	AU 2003-215334	20030220 <--
	US 20030232019	A1	20031218	US 2003-371398	20030220 <--
PRAI	US 2002-359466P	P	20020222	<--	
	US 2002-427845P	P	20021120	<--	
	WO 2003-US5105	W	20030220	<--	

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Particles for inhalation having rapid release properties
AB The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. Formulation of a dry powder inhalant containing DPPC 70, leucine 10, and insulin 20% is disclosed.
AN 2003:512067 HCAPLUS <<LOGINID::20100623>>
DN 139:74074
TI Particles for inhalation having rapid release properties
IN Schmitke, Jennifer L.; Chen, Donghao; Batycky, Richard P.; Edwards, David A.
PA Advanced Inhalation Research, Inc., USA
SO U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 888,126.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030125236	A1	20030703	US 2002-179463	20020624 <--
	US 20020141946	A1	20021003	US 2001-888126	20010622 <--
	EP 1797902	A2	20070620	EP 2006-76387	20011218 <--
	EP 1797902	A3	20071003		
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	US 20080039366	A1	20080214	US 2006-436404	20060518 <--
	JP 2006249099	A	20060921	JP 2006-162862	20060612 <--
	AU 2006243885	A1	20061214	AU 2006-243885	20061128 <--
	AU 2006243885	B2	20070503		
	US 20080226730	A1	20080918	US 2007-860302	20070924 <--
PRAI	US 2000-752109	B2	20001229	<--	

US	2001-888126	A2	20010622	<--
AU	2002-230993	A3	20011218	<--
EP	2001-991253	A3	20011218	<--
JP	2002-554139	A3	20011218	<--
AU	2002-350606	A3	20020624	<--
US	2002-179463	B1	20020624	<--
US	2002-202616	A1	20020723	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L13 ANSWER 18 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Pulmonary delivery of aminoglycosides
AB The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compns. and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compns. and methods are provided for the localized treatment of respiratory infections. Dry powder compns. containing gentamicin were prepared by mixing gentamicin sulfate and excipients (e.g., L-leucine) with a liquid medium to form a solution The solution was spray dried to give a powder composition
AN 2003:511125 HCAPLUS <<LOGINID::20100623>>
DN 139:74044
TI Pulmonary delivery of aminoglycosides
IN Tarara, Thomas E.; Weers, Jeffry G.; Venthoye, Geraldine
PA Nektar Therapeutics, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003053411	A1	20030703	WO 2002-US41733	20021219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2468958	A1	20030703	CA 2002-2468958	20021219 <--
AU 2002361897	A1	20030709	AU 2002-361897	20021219 <--
US 20030129140	A1	20030710	US 2002-327510	20021219 <--
US 7368102	B2	20080506		
EP 1458360	A1	20040922	EP 2002-797527	20021219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005514393	T	20050519	JP 2003-554170	20021219 <--
KR 958235	B1	20100517	KR 2004-709770	20021219 <--
MX 2004005865	A	20040913	MX 2004-5865	20040616 <--
US 20080063606	A1	20080313	US 2007-981986	20071031 <--
PRAI US 2001-342827P	P	20011219	<--	
US 2002-327510	A1	20021219	<--	
WO 2002-US41733	W	20021219	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 19 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Spray drying methods for powder blends
AB A method and apparatus are provided for atomizing a liquid under dispersal conditions suitable for spray drying at a com. plant scale. In one embodiment, a liquid atomizer has a structural body adapted for connection with a spray dryer and a plurality of atomizing nozzles. Each of the atomizing nozzles includes a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas. In another embodiment, a process for producing a powder blend of at least two target substances, e.g., a corticosteroid and a β-blocker, in a single processing step is provided. Blending capabilities were evaluated using buffer solns. consisting of monobasic sodium phosphate or dibasic sodium phosphate with leucin in a 1:1 ratio at 1% total solids concentration
AN 2003:356227 HCAPLUS <<LOGINID::20100623>>
DN 138:358554
TI Spray drying methods for powder blends
IN Snyder, Herman E.; Vosberg, Michael J.; Varga, Christopher M.
PA Inhale Therapeutic Systems, Inc., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003037303	A1	20030508	WO 2002-US34909	20021031	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2464656	A1	20030508	CA 2002-2464656	20021031	<--
	AU 2002342241	A1	20030512	AU 2002-342241	20021031	<--
	AU 2002342241	B2	20070719			
	US 20030124193	A1	20030703	US 2002-284960	20021031	<--
	EP 1446104	A1	20040818	EP 2002-776395	20021031	<--
	EP 1446104	B1	20080716			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
	JP 2005511555	T	20050428	JP 2003-539647	20021031	<--
	AT 401058	T	20080815	AT 2002-776395	20021031	<--
	EP 1992335	A1	20081119	EP 2008-160325	20021031	<--
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI					
	KR 951750	B1	20100409	KR 2004-706672	20021031	<--
	MX 2004004091	A	20040708	MX 2004-4091	20040429	<--
	AU 2007202862	A1	20070712	AU 2007-202862	20070620	<--
	AU 2009202578	A1	20090716	AU 2009-202578	20090626	<--
PRAI	US 2001-336538P	P	20011101	<--		
	AU 2002-342241	A3	20021031	<--		
	EP 2002-776395	A3	20021031	<--		
	WO 2002-US34909	W	20021031	<--		
	AU 2007-202862	A3	20070620			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 20 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI The use of proton sequestering agents in drug formulations
AB Methods are provided for preparing spray-dried, drug-containing particles with improved stability comprising the steps of: (a) selecting a drug, e.g., a therapeutic protein, an aqueous solution, and a proton-sequestering agent; (b) adding the drug and the proton-sequestering agent to the solution to form a feed solution; and (c) spray drying the feed solution to form the spray-dried, drug-containing particles, wherein at least a portion of the proton-sequestering agent remains mixed with the drug in the spray-dried, drug containing particles. Proton sequestering agents are selected from amino acids, oligopeptides, short-chain fatty acids, and carboxylic acid salts. Particles and pharmaceutical formulations comprising the prepared particles as well as methods of use are also provided. For example, to control the degradation rate of parathyroid hormone by decreasing the amount of protons (and water) relative to the amount of the drug, a formulation containing 0.8% parathyroid hormone, 79.2% sucrose, 20% leucine, and 2% disodium citrate was prepared at pH 4, having a 0.5% total solids with a volume of 50 mL. The resulting powder contains 2 mg (0.49 μmol) parathyroid hormone, 193 mg (564 μmol) sucrose, 50 mg (12 μmol) leucine, 5 mg (21 μmol) disodium citrate, and 5 μmol of acid.
AN 2003:334889 HCAPLUS <<LOGINID::20100623>>
DN 138:343903
TI The use of proton sequestering agents in drug formulations
IN Lehrman, S. Russ; Chiang, Hi-Shi; Kuo, Mei-Chang; Zhang, Jiang; Lechuga-Ballesteros, David
PA Inhale Therapeutic Systems, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035051	A2	20030501	WO 2002-US33017	20021016 <--
	WO 2003035051	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002335046	A1	20030506	AU 2002-335046	20021016 <--
	US 20050013867	A1	20050120	US 2004-493182	20040909 <--
PRAI	US 2001-330074P	P	20011019	<--	
	WO 2002-US33017	W	20021016	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 21 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Modulating charge density to produce improvements in the characteristics of spray-dried proteins
AB Methods are provided for preparing spray-dried, drug-containing particles

comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining the solution and the drug and optional excipient, wherein an absolute net charge is associated with the drug and optional excipient as a result of an absolute difference between the pH and effective pI; and (c) spray drying the solution to form the spray-dried, drug-containing particles. Particles and compns. comprising the prepared particles as well as methods of use are also provided. For example, 1 mg/mL of interferon-β was mixed with 9 mg/mL raffinose and titrated with HCl to pH 4.0. The solution was spray dried to form particles for pulmonary delivery with ED of 67%.

AN 2003:334869 HCAPLUS <<LOGINID::20100623>>
DN 138:343893
TI Modulating charge density to produce improvements in the characteristics of spray-dried proteins
IN Lehrman, S. Russ; Stevenson, Cynthia; Yang, Bing
PA Inhale Therapeutic Systems, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035028	A1	20030501	WO 2002-US33016	20021016 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002335045	A1	20030506	AU 2002-335045	20021016 <--
	US 20050123509	A1	20050609	US 2004-493181	20041102 <--
PRAI	US 2001-330073P	P	20011019	<--	
	WO 2002-US33016	W	20021016	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Dry powder inhalation system for transpulmonary administration
AB It is intended to provide a novel dry powder inhalation system for transpulmonary administration. This dry powder inhalation system for transpulmonary administration contains a single dose of the active ingredient and is characterized by comprising a combination of a container packed with a freeze-dried composition having the following properties: (i) being in the form of a non-powder cake; (ii) having a decay index of ≥ 0.015; and (iii) upon an air impact having an air speed of at least 1 m/s and an air flow rate of at least 17 mL/s, being disintegrated into fine particles having an average particle diameter of ≤ 10 μm or an effective particle ratio of ≥ 10%; with a device provided with means

of imparting the above air impact to the freeze-dried composition in the above container and means of discharging the powdery freeze-dried composition having been disintegrated into fine particles from the container. A freeze-dried cake was prepared from interferon-α and isoleucine, and applied to an inhaler of the present invention for transpulmonary powder administration.

AN 2002:977700 HCAPLUS <<LOGINID::20100623>>

DN 138:44733

TI Dry powder inhalation system for transpulmonary administration

IN Yamashita, Chikamasa; Ibaragi, Shigeru; Fukunaga, Yuichiro; Akagi, Akitsuna

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102445	A1	20021227	WO 2002-JP5955	20020614 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EG 24184	A	20081008	EG 2002-661	20020612 <--
	CA 2449954	A1	20021227	CA 2002-2449954	20020614 <--
	AU 2002311213	A1	20030102	AU 2002-311213	20020614 <--
	AU 2002311213	B2	20071213		
	EE 2004000011	A	20040216	EE 2004-11	20020614 <--
	EE 4956	B1	20080215		
	EP 1402913	A1	20040331	EP 2002-736105	20020614 <--
	EP 1402913	B1	20060823		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1516606	A	20040728	CN 2002-811941	20020614 <--
	CN 100427077	C	20081022		
	BR 2002010425	A	20040817	BR 2002-10425	20020614 <--
	HU 2004000217	A2	20040928	HU 2004-217	20020614 <--
	NZ 530044	A	20050930	NZ 2002-530044	20020614 <--
	EP 1688133	A1	20060809	EP 2006-10991	20020614 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1688134	A2	20060809	EP 2006-10993	20020614 <--
	EP 1688134	A3	20091118		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 336989	T	20060915	AT 2002-736105	20020614 <--
	PT 1402913	E	20061229	PT 2002-736105	20020614 <--
	ES 2271266	T3	20070416	ES 2002-736105	20020614 <--
	AP 1861	A	20080831	AP 2003-2945	20020614 <--
	US 7448379	B2	20081111	US 2002-170339	20020614 <--
	IL 159080	A	20090211	IL 2002-159080	20020614 <--
	CN 101366989	A	20090218	CN 2008-10214934	20020614 <--
	ZA 2003009550	A	20041209	ZA 2003-9550	20031209 <--
	IN 2003DN02138	A	20060120	IN 2003-DN2138	20031209 <--

```
     IN 228717            A1    20090220
     MX 2003011541        A     20040319    MX 2003-11541          20031211 <--
     NO 2003005554        A     20040212    NO 2003-5554           20031212 <--
     KR 815216            B1    20080319    KR 2003-716433         20031215 <--
     BG 108517            A     20050228    BG 2004-108517         20040108 <--
     HR 2004000033        A2    20040831    HR 2004-33             20040114 <--
     HR 2004000033        B1    20071130
     JP 4258647           B2    20090430    JP 2004-236727         20040816 <--
     HK 1066748           A1    20090605    HK 2004-109711         20041208 <--
     KR 2007048813        A     20070509    KR 2007-709246         20070423 <--
     KR 906754            B1    20090709
     KR 2007050105        A     20070514    KR 2007-709245         20070423 <--
     KR 907333            B1    20090713
     AU 2008200583        A1    20080228    AU 2008-200583         20080207 <--
     US 20090126732       A1    20090521    US 2008-202220         20080830 <--
     US 20090095293       A1    20090416    US 2008-202221         20081010 <--
     IN 2009DN00786       A     20090529    IN 2009-DN786          20090202 <--
PRAI JP 2001-182504       A     20010615  <--
     JP 2001-400871       A     20011228  <--
     JP 2002-111131       A     20020412  <--
     AU 2002-311213       A3    20020614  <--
     CN 2002-811941       A3    20020614  <--
     EP 2002-736105       A3    20020614  <--
     JP 2003-505028       A3    20020614  <--
     US 2002-170339       A1    20020614  <--
     WO 2002-JP5955       W     20020614  <--
     JP 2002-363158       T     20021213  <--
     IN 2003-DN2138       A3    20031209  <--
     KR 2003-716433       A3    20031215  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  17    THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 23 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   GLP-1 formulations with protracted time action
AB   The present invention encompasses compns. wherein a GLP-1 compound is
     complexed with a basic polypeptide.  The compns. provide a prolonged
     duration of action and can be administered by the pulmonary
     route.
AN   2002:946049  HCAPLUS <<LOGINID::20100623>>
DN   138:44696
TI   GLP-1 formulations with protracted time action
IN   Defelippis, Michael Rosario; Havel, Henry Acken; Mace, Kenneth Francis;
     Ng, Kingman; Sarin, Virender Kumar
PA   Eli Lilly and Company, USA
SO   PCT Int. Appl., 89 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2002098348       A2     20021212    WO 2002-US15137        20020521 <--
     WO 2002098348       A3     20050421
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002308706 A1 20021216 AU 2002-308706 20020521 <--

JP 2005506956 T 20050310 JP 2003-501390 20020521 <--

EP 1542712 A2 20050622 EP 2002-776560 20020521 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

US 20050043228 A1 20050224 US 2003-477034 20031106 <--

US 7144863 B2 20061205

PRAI US 2001-295282P P 20010601 <--

WO 2002-US15137 W 20020521 <--

OS MARPAT 138:44696

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 24 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Particles for inhalation having rapid release properties

AB The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery. Dry powder inhaled insulin formulations are disclosed. Formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. Thus, an insulin powder formulation contained DPPC 70, leucine 10, and insulin 20% by weight

AN 2002:754972 HCAPLUS <<LOGINID::20100623>>

DN 137:268470

TI Particles for inhalation having rapid release properties

IN Schmitke, Jennifer L.; Chen, Donghao; Batycky, Richard P.; Edwards, David A.; Hrkach, Jeffrey S.

PA Advanced Inhalation Research, Inc., USA

SO U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 752,109.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 11

PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 20020141946 A1 20021003 US 2001-888126 20010622 <--

EP 1797902 A2 20070620 EP 2006-76387 20011218 <--

EP 1797902 A3 20071003

R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR

CA 2449439 A1 20030103 CA 2002-2449439 20020624 <--

WO 2003000202 A2 20030103 WO 2002-US20280 20020624 <--

WO 2003000202 A3 20030814

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2002350606	A1	20030108	AU 2002-350606	20020624 <--
AU	2002350606	B2	20060928		
US	20030125236	A1	20030703	US 2002-179463	20020624 <--
EP	1404299	A2	20040407	EP 2002-752100	20020624 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN	1518441	A	20040804	CN 2002-812566	20020624 <--
JP	2005500309	T	20050106	JP 2003-506648	20020624 <--
JP	4067047	B2	20080326		
NZ	530123	A	20070126	NZ 2002-530123	20020624 <--
MX	2003011861	A	20040326	MX 2003-11861	20031218 <--
US	20080039366	A1	20080214	US 2006-436404	20060518 <--
JP	2006249099	A	20060921	JP 2006-162862	20060612 <--
AU	2006243885	A1	20061214	AU 2006-243885	20061128 <--
AU	2006243885	B2	20070503		
US	20080226730	A1	20080918	US 2007-860302	20070924 <--
US	20080227690	A1	20080918	US 2007-860357	20070924 <--
PRAI US	2000-752109	A2	20001229	<--	
US	2001-888126	A	20010622	<--	
AU	2002-230993	A3	20011218	<--	
EP	2001-991253	A3	20011218	<--	
JP	2002-554139	A3	20011218	<--	
AU	2002-350606	A3	20020624	<--	
US	2002-179463	B1	20020624	<--	
WO	2002-US20280	W	20020624	<--	
US	2002-202616	A1	20020723	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L13 ANSWER 25 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Pulmonary delivery of polyene antifungal agents

AB The present invention provides spray-dried polyene antibiotic compns. for oral inhalation to the lung. The compns. demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections. For example, spray drying a nearly neutral pH aqueous solution of amphotericin B with sodium deoxycholate provided a powder having a good dispersibility (an emitted dose of greater than 70%) and a good mass median aerodynamic diameter (MMAD) of less than 3.0 μ.

AN 2002:539453 HCAPLUS <<LOGINID::20100623>>

DN 137:99006

TI Pulmonary delivery of polyene antifungal agents

IN Weickert, Michael; Gordon, Marc S.; Kumar, Sandeep; Yang, Bing; Sarwar, Razaq

PA Inhale Therapeutic Systems, Inc., USA

SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002054868	A2	20020718	WO 2001-US50241	20011221 <--
	WO 2002054868	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6630169	B1	20031007	US 2000-720536	20001222	<--
CA 2432319	A1	20020718	CA 2001-2432319	20011221	<--
AU 2002245181	A1	20020724	AU 2002-245181	20011221	<--
AU 2002245181	B2	20060629			
EP 1343372	A2	20030917	EP 2001-993340	20011221	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004517127	T	20040610	JP 2002-555618	20011221	<--
AU 2002318867	A1	20030410	AU 2002-318867	20021210	<--
MX 2003005655	A	20041203	MX 2003-5655	20030620	<--
KR 743404	B1	20070730	KR 2003-708493	20030621	<--
AU 2006200277	A1	20060216	AU 2006-200277	20060123	<--
AU 2006200277	B2	20080410			
AU 2006200768	A1	20060316	AU 2006-200768	20060224	<--
AU 2006200768	B2	20080717			
AU 2006222737	A1	20061019	AU 2006-222737	20060928	<--
AU 2009212804	A1	20090917	AU 2009-212804	20090826	
PRAI US 2000-257613P	P	20001221	<--		
AU 1999-10644	A3	19980929	<--		
WO 1999-US6855	W	19990331	<--		
AU 2001-61246	A3	20010508	<--		
WO 2001-US50241	W	20011221	<--		
AU 2002-318867	A3	20021210	<--		
AU 2003-204270	A3	20030520	<--		
AU 2006-236049	A3	20061115			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 26 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Particles for inhalation having sustained release properties containing positively charged lipids
AB The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion. In vivo release data showed that powder formulations comprising insulin and pos. charged lipids (1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine or 1,2-distearoyl-sn-glycero-3-ethylphosphocholine) have lower initial burst of insulin than that seen with powder formulations comprising insulin and DPPC and sustained elevated levels at 6-8 h.
AN 2002:521543 HCAPLUS <<LOGINID::20100623>>
DN 137:83673
TI Particles for inhalation having sustained release properties containing positively charged lipids
IN Basu, Sujit K.; Hrkach, Jeffrey S.; Lipp, Michael; Elbert, Katharina; Edwards, David A.

PA Advanced Inhalation Research, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002053190	A2	20020711	WO 2001-US48956	20011218	<--
	WO 2002053190	A3	20030327			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2433335	A1	20020711	CA 2001-2433335	20011218	<--
	CA 2433335	C	20100420			
	AU 2002230993	A1	20020716	AU 2002-230993	20011218	<--
	AU 2002230993	B2	20060202			
	EP 1345629	A2	20030924	EP 2001-991253	20011218	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2005504715	T	20050217	JP 2002-554139	20011218	<--
	EP 1797902	A2	20070620	EP 2006-76387	20011218	<--
	EP 1797902	A3	20071003			
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR					
	US 20080039366	A1	20080214	US 2006-436404	20060518	<--
	JP 2006249099	A	20060921	JP 2006-162862	20060612	<--
	AU 2006243885	A1	20061214	AU 2006-243885	20061128	<--
	AU 2006243885	B2	20070503			
PRAI	US 2000-752109	A	20001229	<--		
	AU 2002-230993	A3	20011218	<--		
	EP 2001-991253	A3	20011218	<--		
	JP 2002-554139	A3	20011218	<--		
	WO 2001-US48956	W	20011218	<--		
	AU 2002-350606	A3	20020624	<--		
	US 2002-202616	A1	20020723	<--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 137:83673
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 27 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
AB A method and a composition are described for the treatment of pulmonary bacterial infections caused by gram-neg. bacteria. The invention also relates to the treatment of infection caused by microorganisms such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Burkholderia cepacia, Stenotrophomonas maltophilia, and multidrug resistant Pseudomonas aeruginosa by using a concentrated formulation of aztreonam, or a salt delivered as an aerosol or dry powder formulation. A purified aztreonam or a salt is milled to a powder having mass median average diams. ranging 1-5 μ by media

milling, jet milling, spray drying, or particle precipitation techniques. Spray drying is achieved by spraying a fine mist of drug solution onto a support and drying the particles. The dry powder formulations are temperature stable and have a physiol. acceptable pH of 4.0-7.5, preferably 5.5 to 7.0, and long shelf-lives.

AN 2002:504571 HCAPLUS <<LOGINID::20100623>>
DN 137:83631
TI Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
IN Montgomery, Alan Bruce
PA Salus Pharma, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051356	A2	20020704	WO 2001-US50062	20011220 <--
	WO 2002051356	A3	20021031		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2433280	A1	20020704	CA 2001-2433280	20011220 <--
	AU 2002231244	A1	20020708	AU 2002-231244	20011220 <--
	AU 2002231244	B2	20060629		
	EP 1353647	A2	20031022	EP 2001-991523	20011220 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001016757	A	20031104	BR 2001-16757	20011220 <--
	JP 2004516302	T	20040603	JP 2002-552504	20011220 <--
	NO 2003002946	A	20030826	NO 2003-2946	20030626 <--
	US 20080050439	A1	20080228	US 2007-729698	20070328 <--
PRAI	US 2000-258423P	P	20001227	<--	
	US 2001-27113	A3	20011220	<--	
	WO 2001-US50062	W	20011220	<--	
	US 2003-654815	A1	20030904	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 28 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI An amino acid, a phospholipid, or a stearate additive in preparation of particles for pulmonary administration
AB A method for making composite active particles for use in a pharmaceutical composition for pulmonary administration comprises a milling step in which particles of active material (drug) are milled in the presence of particles of an additive material, i.e., an amino acid, a phospholipid, or a metal stearate, suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compns. for inhalation prepared by the method. For example, 5 g of micronized salbutamol sulfate (particle size distribution 1-5 μm) and 0.5 g of magnesium stearate were added to a stainless steel milling vessel together with 20

cm3 dichloromethane and 124 g of 3 mm stainless steel balls. The mixture was milled at 550 rpm for 5 h and the powder was recovered by drying and sieving to remove the mill balls. The procedure was repeated using leucine in place of the magnesium stearate. The powders obtained appear to have particles in the size range 0.1-0.5 μm.

AN 2002:428687 HCAPLUS <<LOGINID::20100623>>

DN 137:10986

TI An amino acid, a phospholipid, or a stearate additive in preparation of particles for pulmonary administration

IN Staniforth, John Nicholas; Green, Matthew Michael James; Morton, David Alexander Vodden

PA Vectura Limited, UK

SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002043701	A2	20020606	WO 2001-GB5315	20011130 <--
	WO 2002043701	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2001076575	A2	20011018	WO 2001-GB1606	20010409 <--
	WO 2001076575	A3	20020328		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2429665	A1	20020606	CA 2001-2429665	20011130 <--
	AU 2002022115	A	20020611	AU 2002-22115	20011130 <--
	EP 1337240	A2	20030827	EP 2001-998328	20011130 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004514504	T	20040520	JP 2002-545674	20011130 <--
	JP 4380988	B2	20091209		
	NZ 526059	A	20050527	NZ 2001-526059	20011130 <--
	AU 2002222115	B2	20060928	AU 2002-222115	20011130 <--
	EP 2168571	A2	20100331	EP 2009-173566	20011130 <--
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	US 20040037785	A1	20040226	US 2003-433072	20030912 <--
	US 7736670	B2	20100615		
PRAI	GB 2000-29261	A	20001130	<--	
	GB 2000-30946	A	20001219	<--	
	WO 2001-GB1606	W	20010409	<--	
	GB 2001-24010	A	20011005	<--	
	GB 2000-8660	A	20000407	<--	
	GB 2001-24009	A	20011005	<--	

EP 2001-998327 A3 20011130 <--
WO 2001-GB5315 W 20011130 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 29 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Particles for inhalation having sustained release properties
AB The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. The lipid is a 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)] and a 1,2-diacyl-sn-glycerol-3-phosphate. Release of the agent from the administered particles occurs in a sustained fashion. A DPPC/citrate/insulin (60/10/30) spray drying solution was prepared by dissolving 600 mg DPPC in 600 mL of ethanol, dissolving 100 mg of sodium citrate and 300 mg of insulin in 400 mL of water and then mixing the two solns. to yield 1 L of cosolvent with a total solute concentration of 1 g/L. The solution was then used to produce dry powders using an atomizer.
AN 2002:332667 HCAPLUS <<LOGINID::20100623>>
DN 136:345816
TI Particles for inhalation having sustained release properties
IN Edwards, David A.; Langer, Robert S.; Vanbever, Rita; Mintzes, Jeffrey; Wang, Jue; Chen, Donghao
PA Massachusetts Institute of Technology, USA; The Penn State Research Foundation
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 394,233.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020052310	A1	20020502	US 2000-752106	20001229 <--
	US 5985309	A	19991116	US 1997-971791	19971117 <--
	EP 1498115	A1	20050119	EP 2004-19571	19971117 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6652837	B1	20031125	US 1999-394233	19990913 <--
	US 20030118513	A1	20030626	US 2002-202616	20020723 <--
	US 7048908	B2	20060523		
	US 7628977	B2	20091208	US 2003-420071	20030418 <--
	US 20040062718	A1	20040401		
	US 20080253971	A9	20081016		
	US 20070014738	A1	20070118	US 2006-523914	20060920 <--
PRAI	US 1997-59004P	P	19970915	<--	
	US 1997-971791	A2	19971117	<--	
	US 1999-394233	A2	19990913	<--	
	US 1996-655570	B2	19960524	<--	
	US 1996-739308	A3	19961029	<--	
	US 1997-784421	A1	19970116	<--	

WO	1997-US8895	A2	19970523	<--
EP	1997-947545	A3	19971117	<--
US	1998-211940	A2	19981215	<--
US	2000-569153	A2	20000511	<--
US	2000-752106	B1	20001229	<--
US	2003-420071	A1	20030418	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 136:345816
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L13 ANSWER 30 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Particles for inhalation having insulin sustained release properties
AB The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a multivalent metal cation which is complexed with a therapeutic, prophylactic or diagnostic agent or any combination thereof having a charge capable of complexing with the cation upon association with the agent, a pharmaceutically acceptable carrier and optionally, a multivalent metal cation-containing component wherein the total amount of multivalent metal cation present in the particles is more than 1% weight/weight of the total weight of the agent (% weight/weight). Release of the agent from the administered particles occurs in a sustained fashion. A composition was prepared containing DPPC 58.8, leucine 24.4, zinc chloride 6.4, Na citrate 5.9, and insulin 4.9%.
AN 2002:221109 HCAPLUS <<LOGINID::20100623>>
DN 136:252507
TI Particles for inhalation having insulin sustained release properties
IN Edwards, David A.; Hrkach, Jeffrey S.
PA Advanced Inhalation Research Inc., USA; Alkermes, Inc.
SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U. S. Ser. No. 383,054.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20020034477	A1	20020321	US 2001-822716	20010330 <--
US 7678364	B2	20100316		
US 6956021	B1	20051018	US 1999-383054	19990825 <--
WO 2002078675	A2	20021010	WO 2002-US9697	20020327 <--
WO 2002078675	A3	20021128		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002303177	A1	20021015	AU 2002-303177	20020327 <--
US 20060002996	A1	20060105	US 2005-176841	20050707 <--

```
PRAI US 1999-383054       A2    19990825  <--
     US 1998-97796P       P     19980825  <--
     US 2001-822716       A     20010330  <--
     WO 2002-US9697       W     20020327  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   3     THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT  365   THERE ARE 365 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 31 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Inhalable spray dried 4-helix bundle protein powders having
     minimized aggregation
AB   The present invention provides highly dispersible spray-dried
     powder compns., and in particular, inhalable dry
     powder compns. for aerosolized delivery o the lungs.  The powders
     of the invention are produced by spray drying a 4 α-helix bundle
     protein under conditions which both: (i) protect the protein from
     aggregation and (ii) provide particles suitable for inhalation
     (i.e., demonstrating superior aerosol performance).
AN   2002:122759  HCAPLUS <<LOGINID::20100623>>
DN   136:172776
TI   Inhalable spray dried 4-helix bundle protein powders having
     minimized aggregation
IN   Stevenson, Cynthia; Hastedt, Jayne E.; Lehrman, S. Russ; Chiang, Hi-Shi;
     Bennett, David B.; Lesikar, David; Yang, Bing; Gong, David; Cabot, Kirsten
PA   Inhale Therapeutic Systems, Inc., USA
SO   PCT Int. Appl., 59 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 6
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ----------------      ----   --------    --------------------    --------
PI   WO 2002011695         A2     20020214    WO 2001-US24632         20010806 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2418960            A1     20020214    CA 2001-2418960         20010806 <--
     AU 2001081113         A      20020218    AU 2001-81113           20010806 <--
     EP 1309312            A2     20030514    EP 2001-959572          20010806 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004515467         T      20040527    JP 2002-517033          20010806 <--
     AU 2001281113         B2     20060720    AU 2001-281113          20010806 <--
     TW 283182             B      20070701    TW 2001-90119169        20010806 <--
     US 20020065399        A1     20020530    US 2001-923519          20010807 <--
     US 6569406            B2     20030527
     MX 2003001092         A      20030925    MX 2003-1092            20030204 <--
     US 20030190291        A1     20031009    US 2003-389628          20030314 <--
     US 6838075            B2     20050104
     US 20050186143        A1     20050825    US 2004-991344          20041117 <--
PRAI US 2000-223144P       P      20000807  <--
     US 2000-228634P       P      20000829  <--
     US 2000-240478P       P      20001013  <--
     WO 2001-US24632       W      20010806  <--
```

US 2001-923519 A1 20010807 <--
US 2003-389628 A1 20030314 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L13 ANSWER 32 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of particles for pharmaceutical compositions
AB A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compns. Microfine lactose was placed in a ceramic milling vessel. An additive material and the ceramic milling balls were added. The ball mill was tumbled at 60 rpm for 5 h. This was repeated a number of times with the amount of additive material varied as a percentage of the lactose from 0.25 to 20%. Additive materials used were L-leucine and magnesium stearate. The powder was recovered by sieving to remove the milling balls.
AN 2002:10258 HCAPLUS <<LOGINID::20100623>>
DN 136:74642
TI Preparation of particles for pharmaceutical compositions
IN Staniforth, John Nicholas; Morton, David Alexander Vodden; Musa, Rosella
PA Vectura Limited, UK
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000197	A1	20020103	WO 2001-GB2860	20010627 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001078694	A2	20011025	WO 2001-GB1732	20010417 <--
WO 2001078694	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1719505	A2	20061108	EP 2006-17742	20010417 <--
EP 1719505	A3	20070718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1829533	A2	20070905	EP 2007-110708	20010417 <--
EP 1829533	A3	20071031		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, BA, HR, MK, YU				
CA 2413692	A1	20020103	CA 2001-2413692	20010627 <--

```
     EP 1296651          A1    20030402    EP 2001-947612          20010627 <--
     EP 1296651          B1    20071114
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004501183       T     20040115    JP 2002-504979          20010627 <--
     AU 2001269261       B2    20051117    AU 2001-269261          20010627 <--
     NZ 523246           A     20051223    NZ 2001-523246          20010627 <--
     KR 949539           B1    20100325    KR 2002-717595          20010627 <--
     ZA 2002008066       A     20030805    ZA 2002-8066            20021008 <--
     ZA 2002010225       A     20030618    ZA 2002-10225           20021218 <--
     IN 2002CN02129      A     20050225    IN 2002-CN2129          20021223 <--
     IN 204312           A1    20070629
     US 20030162835      A1    20030828    US 2003-312488          20030311 <--
     HK 1056115          A1    20080808    HK 2003-106950          20030926 <--
PRAI EP 2000-113608      A     20000627  <--
     GB 2000-29263       A     20001130  <--
     WO 2001-GB1732      W     20010417  <--
     GB 2000-9469        A     20000417  <--
     EP 2001-921625      A3    20010417  <--
     EP 2001-931612      A3    20010417  <--
     WO 2001-GB2860      W     20010627  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 33 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Powders for use in a dry powder inhaler
AB   A powder for use in a dry powder inhaler
     comprises an active material and an indicator material that is capable of
     indicating to a patient that a dose of the active material has been
     administered.  The powder for use in an inhaler device
     and/or an inhaler device containing the powder may be such
     that a fine particle fraction of at least 35% is
     generated.  Thus, a formulation contained sodium cromoglycate 50.0,
     lactose 48.5, and menthol 1.5%.
AN   2001:816434  HCAPLUS <<LOGINID::20100623>>
DN   135:362566
TI   Powders for use in a dry powder inhaler
IN   Staniforth, John Nicholas; Morton, David Alexander Vodden; Meakin, Brian
     John; Ganderton, David
PA   Vectura Limited, UK
SO   PCT Int. Appl., 28 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    -------------------     --------
PI   WO 2001082906        A1    20011108    WO 2001-GB1942          20010503 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1278516          A1    20030129    EP 2001-928057          20010503 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

```
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 20030186843       A1     20031002    US 2003-275023          20030602 <--
PRAI GB 2000-10709        A      20000503  <--
     WO 2001-GB1942       W      20010503  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RE.CNT  4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 34 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Formulations containing fine lactose for use in inhaler
     devices
AB   A formulation for an inhaler device comprises carrier particles
     having a diameter of at least 50 μm and a mass median diameter of at least
     175 μm; active particles; and additive material to which is able to
     promote release of the active particles from the carrier particles on
     actuation of the inhaler device.  The formulation has excellent
     flowability even at relatively high fine particle
     contents.  A formulation contained lactose, salbutamol sulfate, microfine
     lactose, and leucine.
AN   2001:780655  HCAPLUS <<LOGINID::20100623>>
DN   135:335150
TI   Formulations containing fine lactose for use in inhaler
     devices
IN   Staniforth, John Nicholas; Morton, David Alexander Vodden; Gill, Rajbir;
     Brambilla, Gaetano; Musa, Rossella; Ferrarini, Lorenzo
PA   Vectura Ltd., UK
SO   PCT Int. Appl., 63 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 11
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2001078694        A2    20011025    WO 2001-GB1732         20010417 <--
     WO 2001078694        A3    20020314
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2406201           A1     20011025    CA 2001-2406201        20010417 <--
     AU 2001048581        A      20011030    AU 2001-48581          20010417 <--
     AU 784719            B2     20060601
     GB 2363987           A      20020116    GB 2001-9431           20010417 <--
     GB 2363988           A      20020116    GB 2001-9432           20010417 <--
     EP 1276472           A2     20030122    EP 2001-921610         20010417 <--
     EP 1276472           B1     20061220
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     BR 2001010141        A      20030128    BR 2001-10141          20010417 <--
     HU 2003000490        A2     20030728    HU 2003-490            20010417 <--
     JP 2003530425        T      20031014    JP 2001-575995         20010417 <--
     NZ 521887            A      20040625    NZ 2001-521887         20010417 <--
     AT 339195            T      20061015    AT 2001-931612         20010417 <--
     EP 1719505           A2     20061108    EP 2006-17742          20010417 <--
     EP 1719505           A3     20070718
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

```
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     AT 348603          T     20070115    AT 2001-921610          20010417 <--
     PT 1276472         E     20070228    PT 2001-921610          20010417 <--
     ES 2272473         T3    20070501    ES 2001-931612          20010417 <--
     ES 2275669         T3    20070616    ES 2001-921610          20010417 <--
     EP 1829533         A2    20070905    EP 2007-110708          20010417 <--
     EP 1829533         A3    20071031
        R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
            NL, PT, SE, TR, AL, BA, HR, MK, YU
     AT 377416          T     20071115    AT 2001-921625          20010417 <--
     ES 2292576         T3    20080316    ES 2001-921625          20010417 <--
     CA 2413692         A1    20020103    CA 2001-2413692         20010627 <--
     WO 2002000197      A1    20020103    WO 2001-GB2860          20010627 <--
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
            UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1296651         A1    20030402    EP 2001-947612          20010627 <--
     EP 1296651         B1    20071114
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004501183      T     20040115    JP 2002-504979          20010627 <--
     AU 2001269261      B2    20051117    AU 2001-269261          20010627 <--
     NZ 523246          A     20051223    NZ 2001-523246          20010627 <--
     AT 378039          T     20071115    AT 2001-947612          20010627 <--
     PT 1296651         E     20080212    PT 2001-947612          20010627 <--
     ES 2292598         T3    20080316    ES 2001-947612          20010627 <--
     EP 1913939         A1    20080423    EP 2007-120591          20010627 <--
        R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
            NL, PT, SE, TR
     CN 100551358       C     20091021    CN 2001-811888          20010627 <--
     KR 949539          B1    20100325    KR 2002-717595          20010627 <--
     ZA 2002008066      A     20030805    ZA 2002-8066            20021008 <--
     NO 2002004971      A     20021217    NO 2002-4971            20021016 <--
     MX 2002010213      A     20050701    MX 2002-10213           20021016 <--
     IN 2002CN01699     A     20050211    IN 2002-CN1699          20021017 <--
     IN 211544          A1    20071214
     ZA 2002010225      A     20030618    ZA 2002-10225           20021218 <--
     US 20030162835     A1    20030828    US 2003-312488          20030311 <--
     US 20030175214     A1    20030918    US 2003-257790          20030505 <--
     HK 1056115         A1    20080808    HK 2003-106950          20030926 <--
PRAI GB 2000-9469       A     20000417  <--
     EP 2000-113608     A     20000627  <--
     GB 2000-29263      A     20001130  <--
     EP 2001-921625     A3    20010417  <--
     EP 2001-931612     A3    20010417  <--
     WO 2001-GB1732     W     20010417  <--
     EP 2001-947612     A3    20010627  <--
     WO 2001-GB2860     W     20010627  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   5     THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 35 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Modulation of release from dry powder formulations
```

AB Particles which include a bioactive agent are prepared to have a desired matrix transition temperature Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release of the drug can be obtained by forming particles which have a high matrix transition temperature, while fast release can be obtained by forming particles which have a low matrix transition temperature Preferred particles include one or more phospholipids. Thus, 20% albumin was mixed with 80% 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (I) or 1,2-distearoyl-sn-glycero-phosphahtdiylcholine (II) and spray-dried using 70% ethanol and 30% water. Matrix transition temperature for particles formulated with I was lower than that for particles formulated with II.

AN 2001:152464 HCAPLUS <<LOGINID::20100623>>

DN 134:198097

TI Modulation of release from dry powder formulations

IN Basu, Sujit K.; Hrkach, Jeffrey S.; Caponetti, Giovanni; Lipp, Michael M.; Elbert, Katharina; Li, Wen-I.

PA Advanced Inhalation Research, Inc., USA

SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001013891	A2	20010301	WO 2000-US23048	20000823	<--
	WO 2001013891	A3	20010726			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	CA 2382821	A1	20010301	CA 2000-2382821	20000823	<--
	EP 1210067	A2	20020605	EP 2000-957674	20000823	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
	JP 2003507410	T	20030225	JP 2001-518029	20000823	<--
	AU 763041	B2	20030710	AU 2000-69259	20000823	<--
PRAI	US 1999-150742P	P	19990825	<--		
	WO 2000-US23048	W	20000823	<--		

OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 36 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Powders consisting of particles with a perfectly smooth surface, for use as carriers for the preparation of inhalation mixtures with micronized drugs and method for their preparation

AB Carriers for use in the preparation of mixts. for inhalation powders intended for pulmonary administration of micronized drugs by means of a dry powder inhaler and the method for their preparation are described. An inhalation powder of beclometasone dipropionate mixed with smoother α-lactose monohydrate carrier was prepared

AN 2001:63851 HCAPLUS <<LOGINID::20100623>>

DN 134:120962

TI Powders consisting of particles with a perfectly smooth surface, for use

as carriers for the preparation of inhalation mixtures with micronized drugs and method for their preparation

IN Caponetti, Giovanni; Catellani, Pier Luigi; Bettini, Ruggero; Colombo, Paolo; Ventura, Paolo

PA Chiesi Farmaceutici S.p.A., Italy

SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001005429	A2	20010125	WO 2000-EP6690	20000713 <--
WO 2001005429	A3	20011004		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 99MI1582	A1	20010116	IT 1999-MI1582	19990716 <--
EP 1196146	A2	20020417	EP 2000-956180	20000713 <--
EP 1196146	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
BR 2000012351	A	20020611	BR 2000-12351	20000713 <--
AT 339191	T	20061015	AT 2000-956180	20000713 <--
ES 2272313	T3	20070501	ES 2000-956180	20000713 <--
US 6780508	B1	20040824	US 2002-30686	20020416 <--
US 20050118113	A1	20050602	US 2004-806240	20040323 <--
US 7399528	B2	20080715		
PRAI IT 1999-MI1582	A	19990716	<--	
WO 2000-EP6690	W	20000713	<--	
US 2002-30686	A1	20020416	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 37 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Pulmonary administration of dry powder formulations for treating infertility

AB Provided are stabilized follicle stimulating protein (FSP) dry powder comps. for aerosolized delivery to the deep lung, methods of preparing and administering such compns., and methods for treating infertility involving administering the dry powders by pulmonary delivery to the deep lung.

AN 2000:741950 HCAPLUS <<LOGINID::20100623>>

DN 133:313613

TI Pulmonary administration of dry powder formulations for treating infertility

IN Nagarajan, Sudha; Patton, John S.; Bennett, David B.; Greene, Joanne; Chiang, Hi-Shi; Stults, Cheryl L. M.; Venthoye, Geraldine; Allen, Darrel Lavern; Hughes, Benjamin Lee; Stiff-Torvik, Mary; Wolff, Ronald Keith; Roeder, William David

PA Inhale Therapeutics, Inc., USA; Eli Lilly and Company

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061178	A1	20001019	WO 2000-US9869	20000413 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2369262	A1	20001019	CA 2000-2369262	20000413 <--
	EP 1169053	A1	20020109	EP 2000-920245	20000413 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002541213	T	20021203	JP 2000-610510	20000413 <--
	AU 779869	B2	20050217	AU 2000-40820	20000413 <--
	TW 277425	B	20070401	TW 2000-89106884	20000413 <--
	US 7112341	B1	20060926	US 2001-958722	20011011 <--
PRAI	US 1999-129121P	P	19990413	<--	
	US 1999-130099P	P	19990420	<--	
	WO 2000-US9869	W	20000413	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 38 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Methods and compositions for the dry powder formulation of interferons
AB Methods and compns. are provided for spray-dried, interferon-based dry powder compns., particularly interferon-beta. The compns. are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN. Approx. 50 mL of 10 mM sodium chloride solution of natural human IFN-beta comprising approx. 2 mg/mL human serum albumin was spray dried to give a composition comprising IFN-beta 1.9, and carrier (75.8% human serum albumin, 22.3% NaCl) 98.1%.
AN 2000:680347 HCAPLUS <<LOGINID::20100623>>
DN 133:256828
TI Methods and compositions for the dry powder formulation of interferons
IN Platz, Robert M.; Kimura, Shigenobu; Satoh, Yu-ichiro; Foster, Linda C.
PA Inhale Therapeutics Systems, Inc., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6123936	A	20000926	US 1999-444116	19991122 <--
	EP 940154	A2	19990908	EP 1999-110369	19920702 <--
	EP 940154	B1	20070418		

```
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
     EP 1693080          A2    20060823    EP 2006-9725          19920702 <--
     EP 1693080          A3    20070725
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC
     AT 359842           T     20070515    AT 1999-110369        19920702 <--
     ES 2284226          T3    20071101    ES 1999-110369        19920702 <--
     US 20030072718      A1    20030417    US 2002-245704        20020918 <--
PRAI US 1991-724915      A     19910702  <--
     EP 1992-914592      A3    19920702  <--
     EP 1999-110369      A3    19920702  <--
     US 1994-246034      B2    19940518  <--
     WO 1995-US6008      W     19950515  <--
     US 1997-737724      A1    19970714  <--
     US 1999-444116      A1    19991122  <--
     US 2000-506426      A1    20000217  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   8     THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 39 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Pharmaceutical powders comprising particles of an amino acid
AB   Particles of an amino acid such as leucine may be formed from an amino
     acid vapor, for example by aerosol condensation, or by spray drying.  The
     amino acid particles have a bulk d. of not more than 0.1 gcm-3 or have a
     mass median aerodynamic diameter of not more than 10 <mm or are in the form
     of flakes having a thickness of not more than 100 <mm.  The inclusion of
     the particles of amino acid in powder for use in dry
     powder inhalers has been found to improve the respirable
     fraction of the active material in the powder.  Ground L-leucine
     particles were suspended from a fluidized bed by a flow of air and carried
     in a gas flow into the tube furnace, which was at a temperature ranging from
     150-300° and sublimed.  The vapor emitted from the furnace was
     mixed with cool air giving a cloud of condensed particles that were
     subsequently collected in a cyclone and membrane filter.  The balk d. of
     the powder was 0.04 gcm-3.  A mixture of salbutamol sulfate and 1%
     low d. leucine was prepared  The powder flow and handling
     performance of the salbutamol powder was significantly improved,
     with minimal adhesion to glass walls compared with the milled leucine
     mixture
AN   2000:401625  HCAPLUS <<LOGINID::20100623>>
DN   133:48937
TI   Pharmaceutical powders comprising particles of an amino acid
IN   Ganderton, David; Morton, David Alexander Vodden; Lucas, Paul
PA   Vectura Limited, UK
SO   PCT Int. Appl., 45 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2000033811       A2     20000615    WO 1999-GB4156         19991209 <--
     WO 2000033811       A3     20001012
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
```

```
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2353448          A1    20000615    CA 1999-2353448        19991209 <--
     CA 2353448          C     20100223
     BR 9916102          A     20010904    BR 1999-16102          19991209 <--
     EP 1137399          A2    20011004    EP 1999-958404         19991209 <--
     EP 1137399          B1    20030514
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO
     TR 2001001591       T2    20011121    TR 2001-1591           19991209 <--
     HU 2001004513       A2    20020328    HU 2001-4513           19991209 <--
     HU 2001004513       A3    20031229
     JP 2002531487       T     20020924    JP 2000-586305         19991209 <--
     JP 4410942          B2    20100210
     AT 240093           T     20030515    AT 1999-958404         19991209 <--
     NZ 511965           A     20030926    NZ 1999-511965         19991209 <--
     PT 1137399          E     20030930    PT 1999-958404         19991209 <--
     ES 2198973          T3    20040201    ES 1999-958404         19991209 <--
     AU 770461           B2    20040219    AU 2000-15777          19991209 <--
     SK 284775           B6    20051103    SK 2001-777            19991209 <--
     MX 2001005584       A     20030714    MX 2001-5584           20010604 <--
     IN 2001CN00786      A     20050304    IN 2001-CN786          20010607 <--
     NO 2001002825       A     20010608    NO 2001-2825           20010608 <--
     US 6989155          B1    20060124    US 2001-857392         20011207 <--
PRAI GB 1998-27145       A     19981209  <--
     WO 1999-GB4156      W     19991209  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   12     THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
RE.CNT  3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 40 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Excipient powders for inhalable drugs
AB   The present invention relates to inhalable drugs in particulate
     form.  More specifically, the present invention is directed to an
     excipient powder that comprises a coarse first fraction having a
     particle size of ≥ 10 μm, a   fine second
     fraction having a particle size of < 10 μm and a third
     fraction consisting of ternary agents.  The excipient powder has
     been found to be beneficial in the administration of pharmaceuticals to
     the pulmonary system.  A carrier formulation was prepared containing
     coarse lactose (> 80 % by mass over 50 μm in size) 89,  fine
     lactose (> 90 % by mass < 10 μm in size) 10, and  fine
     L-leucine (> 90 % by mass < 10 μm in size) 1 %.  The carrier
     formulation was blended with 2 % of a corticosteroid.  The mean respirable
     fraction was .apprx. 60 %, compared to .apprx. 40 % for the formulation
     without L-leucine.
AN   2000:401604  HCAPLUS <<LOGINID::20100623>>
DN   133:34444
TI   Excipient powders for inhalable drugs
IN   Embleton, Jonathan Kenneth
PA   R.P. Scherer, Inc., USA
SO   PCT Int. Appl., 13 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   WO 2000033789       A2     20000615    WO 1999-US28608        19991203 <--
     WO 2000033789       A3     20000914
          W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
```

```
            DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
            JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
            MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
            TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 2000020383        A     20000626    AU 2000-20383          19991203 <--
PRAI GB 1998-26783       A     19981204  <--
    WO 1999-US28608      W     19991203  <--
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 41 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Enhancement of small particle size dry powder aerosol
     formulations using an ultra low density additive
AB   Low d. L-leucine was used to modify the bulk properties of salbutamol
     formulations.  The potential of L-leucine to facilitate emptying of
     formulation of a model small mol. drug from a multi-dose pre-metered
     inhaler device was examined
AN   1999:707291  HCAPLUS <<LOGINID::20100623>>
DN   132:40462
TI   Enhancement of small particle size dry powder aerosol
     formulations using an ultra low density additive
AU   Lucas, Paul; Anderson, Kerry; Potter, Ursula J.; Staniforth, John N.
CS   Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2
     7AY, UK
SO   Pharmaceutical Research (1999), 16(10), 1643-1647
     CODEN: PHREEB; ISSN: 0724-8741
PB   Kluwer Academic/Plenum Publishers
DT   Journal
LA   English
OSC.G   50    THERE ARE 50 CAPLUS RECORDS THAT CITE THIS RECORD (50 CITINGS)
RE.CNT  13    THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 42 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Aerosol composition comprising a propellant and a particulate material
AB   An aerosol composition comprising a propellant and a first particulate material
     comprising particles having a median aerodynamic diameter within the range
     0.05 to 11 μm, such as a medicament suitable for  pulmonary
     inhalation, and a second particulate material comprising particles
     having a median volume diameter within the range 15 to 200 μm.  The presence
     of the second particulate material provides good suspension properties,
     particularly where the propellant is a hydrofluoroalkane.  An aerosol
     inhaler was prepared comprising budesonide (median particle
     size 1.89 μm), lactose (median diam 90-63μm) and HFA-134a.  The ease
     of dispersion and suspension quality of the inhaler was assessed
     and it was good.
AN   1999:659213  HCAPLUS <<LOGINID::20100623>>
DN   131:276982
TI   Aerosol composition comprising a propellant and a particulate material
IN   Dickinson, Paul Alfred; Warren, Simon John
PA   University College Cardiff Consultants Limited, UK; Cardiff Scintigraphics
     Limited
SO   PCT Int. Appl., 41 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9951205	A1	19991014	WO 1999-GB1019	19990401 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2327336	A1	19991014	CA 1999-2327336	19990401 <--
	CA 2327336	C	20080708		
	AU 9931620	A	19991025	AU 1999-31620	19990401 <--
	AU 761518	B2	20030605		
	BR 9909394	A	20001205	BR 1999-9394	19990401 <--
	EP 1069887	A1	20010124	EP 1999-913508	19990401 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002510614	T	20020409	JP 2000-541977	19990401 <--
	CN 1215832	C	20050824	CN 1999-806712	19990401 <--
	MX 2000009660	A	20030714	MX 2000-9660	20001002 <--
	ZA 2000005374	A	20020103	ZA 2000-5374	20001003 <--
	US 6737044	B1	20040518	US 2001-647331	20010130 <--
	US 20050249674	A1	20051110	US 2003-668840	20030923 <--
	US 7481995	B2	20090127		
PRAI	GB 1998-7232	A	19980403 <--		
	WO 1999-GB1019	W	19990401 <--		
	US 2001-647331	A1	20010130 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 43 OF 44 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Powders for use in dry powder pharmaceutical inhalers
AB A powder for use in a dry powder pharmaceutical inhaler comprises active material and additive material. The additive material comprises an anti-adherent material and the powder includes at least 60 % by weight of active material. The inclusion of the additive material in the powder has been found to give an increased respirable fraction of the active material. Leucine powder (I) (95% of which having particle size ≤159 μm) 2 g and terbutaline sulfate (II) (having mass aerodynamic diameter of 2.1 μm) 198 g were mixed and agglomerated using a milling procedure for 6 h, the agglomerated powder was then filled into a Turbohaler. Each metered dose contained I 5, and II 500 μg.
AN 1997:207747 HCAPLUS <<LOGINID::20100623>>
DN 126:203732
OREF 126:39307a,39310a
TI Powders for use in dry powder pharmaceutical inhalers
IN Staniforth, John Nicholas
PA Co-Ordinated Drug Development Ltd., UK; Staniforth, John Nicholas
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703649	A1	19970206	WO 1996-GB1783	19960724 <--

```
        W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,
            EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR,
            LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
            SD, SE
        RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
            IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM
     ZA 9606237            A     19970211    ZA 1996-6237          19960723 <--
     AU 9666203            A     19970218    AU 1996-66203         19960724 <--
     EP 871430             A1    19981021    EP 1996-925828        19960724 <--
     EP 871430             B1    20031217
     EP 871430             B2    20090909
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI
     JP 11509546           T     19990824    JP 1997-506460        19960724 <--
     JP 4103939            B2    20080618
     EP 1213012            A2    20020612    EP 2002-3204          19960724 <--
     EP 1213012            A3    20021204
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI
     AT 256451             T     20040115    AT 1996-925828        19960724 <--
     PT 871430             E     20040430    PT 1996-925828        19960724 <--
     ES 2213180            T3    20040816    ES 1996-925828        19960724 <--
     CA 2226657            C     20090203    CA 1996-2226657       19960724 <--
     US 6475523            B1    20021105    US 1998-65            19980616 <--
     US 20030113272        A1    20030619    US 2002-236070        20020905 <--
     US 20050152849        A1    20050714    US 2005-54074         20050209 <--
PRAI GB 1995-15182         A     19950724  <--
     EP 1996-925828        A3    19960724  <--
     WO 1996-GB1783        W     19960724  <--
     US 1998-65            A1    19980616  <--
     US 2002-236070        B1    20020905  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   26     THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
RE.CNT  2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 44 OF 44  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Carrier particles for use in dry powder inhalers
AB   A powder for use in a dry powder inhaler
     includes active particles and carrier particles for carrying the active
     particles.  The powder further includes additive material on the
     surface of the carrier particles to promote the release of the active
     particles from the carrier particles on actuation of the inhaler
     .  The powder is such that the active particles are not liable
     to be released from the carrier particles before actuation of the
     inhaler.  The inclusion of additive material in the powder
     gives an increased respirable fraction of the active material.  Lactose
     particles (particle size 90-125 μm) were mixed with leucine
     (diameter ≤150 μm), then with beclomethasone dipropionate to obtain
     powders for inhalation.
AN   1996:584137  HCAPLUS <<LOGINID::20100623>>
DN   125:204578
OREF 125:38113a,38116a
TI   Carrier particles for use in dry powder inhalers
IN   Staniforth, John Nicholas
PA   Co-Ordinated Drug Development Limited, UK
SO   PCT Int. Appl., 73 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9623485	A1	19960808	WO 1996-GB215	19960131	<--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE					
	CA 2211874	A1	19960808	CA 1996-2211874	19960131	<--
	CA 2211874	C	20060829			
	ZA 9600721	A	19960819	ZA 1996-721	19960131	<--
	AU 9645456	A	19960821	AU 1996-45456	19960131	<--
	AU 699131	B2	19981126			
	EP 806938	A1	19971119	EP 1996-901439	19960131	<--
	EP 806938	B1	20031217			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV					
	BR 9607490	A	19971223	BR 1996-7490	19960131	<--
	CN 1179097	A	19980415	CN 1996-192676	19960131	<--
	CN 1303974	C	20070314			
	JP 10513174	T	19981215	JP 1996-523350	19960131	<--
	JP 4042867	B2	20080206			
	HU 9802209	A2	19990201	HU 1998-2209	19960131	<--
	HU 9802209	A3	20000628			
	EP 1159955	A1	20011205	EP 2001-120610	19960131	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV					
	EP 1232745	A1	20020821	EP 2002-7397	19960131	<--
	EP 1232745	B1	20070307			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV					
	SK 282630	B6	20021008	SK 1997-1036	19960131	<--
	AT 256450	T	20040115	AT 1996-901439	19960131	<--
	PL 186757	B1	20040227	PL 1996-321572	19960131	<--
	PT 806938	E	20040531	PT 1996-901439	19960131	<--
	ES 2213172	T3	20040816	ES 1996-901439	19960131	<--
	CZ 294259	B6	20041110	CZ 1997-2443	19960131	<--
	EP 1666023	A2	20060607	EP 2006-4066	19960131	<--
	EP 1666023	A3	20090506			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV					
	AT 355822	T	20070315	AT 2002-7397	19960131	<--
	PT 1232745	E	20070430	PT 2002-7397	19960131	<--
	ES 2278828	T3	20070816	ES 2002-7397	19960131	<--
	FI 9703151	A	19970930	FI 1997-3151	19970730	<--
	FI 119676	B1	20090213			
	NO 9703502	A	19970930	NO 1997-3502	19970730	<--
	NO 324037	B1	20070730			
	US 6153224	A	20001128	US 1997-875391	19970925	<--
	US 6521260	B1	20030218	US 2000-680863	20001006	<--
	US 20030170183	A1	20030911	US 2002-306865	20021127	<--
	US 7011818	B2	20060314			
	US 20060029552	A1	20060209	US 2005-202741	20050811	<--
	US 7718163	B2	20100518			
PRAI	GB 1995-1841	A	19950131	<--		
	GB 1995-21937	A	19951026	<--		
	GB 1995-15182	A	19950724	<--		
	EP 1996-901439	A3	19960131	<--		
	EP 2002-7397	A3	19960131	<--		
	WO 1996-GB215	W	19960131	<--		

```
     US 1997-875391        A1    19970925  <--
     US 2000-680863        A1    20001006  <--
     US 2002-306865        A1    20021127  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   41     THERE ARE 41 CAPLUS RECORDS THAT CITE THIS RECORD (45 CITINGS)
RE.CNT  4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
```